Thermostable polymerases having altered fidelity and methods of identifying and using same

ABSTRACT

The present invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example, the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant.

[0001] This application claims the benefit of priority of U.S.Provisional Application serial No. 60/031,496, filed Nov. 27, 1996, theentire contents of which is incorporated herein by reference.

[0002] This invention was made with government support under grantnumber OIG-R35-CA-39903 awarded by the National Institutes of Health andgrant number BIR9214821 awarded by the National Science Foundation. Thegovernment has certain rights in the invention.

BACKGROUND OF THE INVENTION

[0003] The present invention relates generally to thermostablepolymerases and more specifically to methods for identifying polymerasemutants having desired fidelity.

[0004] Every living organism requires genetic material, deoxyribonucleicacid (DNA), to pass a unique collection of characteristics to itsoffspring. Genes are discreet segments of the DNA and provide theinformation required to generate a new organism. Even simple organisms,such as bacteria, contain thousands of genes, and the number is manyfold greater in complex organisms such as humans. Understanding thecomplexities of the development and functioning of living organismsrequires knowledge of these genes. However, the amount of DNA that canbe isolated for study has often been limiting.

[0005] A major breakthrough in the study of genes was the development ofthe polymerase chain reaction (PCR). PCR amplifies genes or portions ofgenes by making many identical copies, allowing isolation of genes fromvery tiny amounts of DNA. The motors for PCR are DNA polymerases thatcopy the DNA of each gene during each round of DNA synthesis. Usingoligonucleotides that determine the start and termination of DNAsynthesis, a single gene can be replicated into millions of copies. Thisprocess has created a revolution in biotechnology and has been usedextensively for the identification of mutant genes that are responsiblefor or associated with inherited human diseases. It is now possible toidentify a mutant gene in a single cell, amplify the gene a milliontimes, and establish the nature of the mutation. One application ofidentifying a mutant gene is the determination of genetic susceptibilityto disease, which can be mapped by gene amplification and DNAsequencing.

[0006] DNA polymerases function in cells as the enzymes responsible forthe synthesis of DNA. They polymerize deoxyribonucleoside triphosphatesin the presence of a metal activator, such as Mg²⁺, in an order dictatedby the DNA template or polynucleotide template that is copied. Eventhough the template dictates the order of nucleotide subunits that arelinked together in the newly synthesized DNA, these enzymes alsofunction to maintain the accuracy of this process. The contribution ofDNA polymerases to the fidelity of DNA synthesis is mediated by twomechanisms. First, the geometry of the substrate binding site in DNApolymerases contributes to the selection of the complementarydeoxynucleoside triphosphates. Mutations within the substrate bindingsite on the polymerase can alter the fidelity of DNA synthesis. Second,many DNA polymerases contain a proof-reading 3′-5′ exonuclease thatpreferentially and immediately excises non-complementary deoxynucleosidetriphosphates if they are added during the course of synthesis. As aresult, these enzymes copy DNA in vitro with a fidelity varying from5×10⁻⁴ (1 error per 2000 bases) to 10⁻⁷ (1 error per 10⁷ bases) (Fry andLoeb, Animal Cell DNA Polymerases, pp. 221, CRC Press, Inc., Boca Raton,Fla. (1986); Kunkel, T. A., J. Biol. Chem. 267:18251-18254(1992)).

[0007] In vivo, DNA polymerases participate in a spectrum of DNAsynthetic processes including DNA replication, DNA repair,recombination, and gene amplification (Kornberg and Baker, DNAReplication, pp. 929, W.H. Freeman and Co., New York (1992)). Duringeach DNA synthetic process, the DNA template is copied once or at most afew times to produce identical replicas. In vitro DNA replication, incontrast, can be repeated many times, for example, during PCR.

[0008] In the initial studies with PCR, the DNA polymerase was added atthe start of each round of DNA replication. Subsequently, it wasdetermined that thermostable DNA polymerases could be obtained frombacteria that grow at elevated temperatures, and these enzymes need tobe added only once. At the elevated temperatures used during-PCR, theseenzymes would not denature. As a result, one can carry out repetitivecycles of polymerase chain reactions without adding fresh enzymes at thestart of each synthetic addition process. The commercial market for thesale of DNA polymerases from thermostable organisms can beconservatively estimated at 200 million dollars per year. DNApolymerases, particularly thermostable polymerases, are the key to alarge number of techniques in recombinant DNA studies and in medicaldiagnosis of disease.

[0009] Due to the importance of DNA polymerases in biotechnology andmedicine, it would be highly advantageous to generate DNA polymeraseshaving desired enzymatic properties such as altered fidelity. However,the ability to predict the effect of introducing an amino acid mutationinto the sequence of a protein remains very limited. Even whenstructural information is available for the protein of interest, it isoften very difficult to predict the effect of mutations of specificamino acid residues on the function of that protein. In particular, itis extremely difficult to predict amino acid substitutions that willalter the activity of an enzyme to achieve a desirable change.

[0010] Despite the limitations in predicting the effect of introducingamino acid substitutions into proteins, a number of mutant DNApolymerases have been discovered, or have been created by site-specificmutagenesis, and have been used in PCR amplification (Tabor andRichardson, Proc. Natl. Acad. Sci. USA 92:6339-6343 (1995)). Some ofthese mutant polymerases offer particular advantages with respect tothermostability, processivity, length of the newly synthesized DNAproduct, or fidelity of DNA synthesis. Those that are more accurate forthe most part contain a 3′-5′ exonuclease activity that removesmisincorporated bases prior to adding the next nucleotide during DNAsynthesis. However, the current spectrum of mutant DNA polymerases isquite limited. For the most part, these mutants have been obtained byintroducing a single base substitution at a specified site, purifyingthe enzyme and studying the changes in catalytic activity (Joyce andSteitz, Annu. Rev. Biochem. 63:777-822 (1994)). These laborious andstep-wise procedures have been necessary due to the lack of adequateknowledge to predict the effects of most single amino acid substitutionsand due to the lack of rules for predicting the effects of multiplesimultaneous substitutions.

[0011] Thus, there exists a need for rapid and efficient methods toproduce and screen for modified polymerases having desired fidelity inpolynucleotide synthesis. The present invention satisfies this need andprovides related advantages as well.

SUMMARY OF THE INVENTION

[0012] The present invention provides a method for identifying athermostable polymerase having altered fidelity. The method consists ofgenerating a random population of polymerase mutants by mutating atleast one amino acid residue of a thermostable polymerase and screeningthe population for one or more active polymerase mutants by geneticselection. For example, the invention provides a method for identifyinga thermostable polymerase having altered fidelity by mutating at leastone amino acid residue in an active site O-helix of a thermostablepolymerase. The invention also provides thermostable polymerases andnucleic acids encoding thermostable polymerases having altered fidelity,for example, high fidelity polymerases and low fidelity polymerases. Theinvention additionally provides a method for identifying one or moremutations in a gene by amplifying the gene with a high fidelitypolymerase. The invention further provides a method for accuratelycopying repetitive nucleotide sequences using a high fidelity polymerasemutant. The invention also provides a method for diagnosing a geneticdisease using a high fidelity polymerase mutant. The invention furtherprovides a method for randomly mutagenizing a gene by amplifying thegene using a low fidelity polymerase mutant.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013]FIG. 1 shows the nucleotide and amino acid sequence of Taq DNApolymerase I (SEQ ID NOS:1 and 2, respectively).

[0014]FIG. 2 shows a compilation of amino acid substitutions identifiedin a screen of Taq DNA polymerase I mutants. Panel A shows singlemutations, which were identified in the screen of a 9% library, listedunder the wild type amino acids. Panel B shows the sequence of multiplysubstituted mutants identified in the screen of a 9% library. Panel Cshows mutations selected from a totally random library of selected aminoacids.

[0015]FIG. 3 shows the spectrum of single base changes generated in aforward mutation assay by Taq DNA polymerase I mutant Thr664Arg.

DETAILED DESCRIPTION OF THE INVENTION

[0016] The invention is directed to methods for screening andidentifying thermostable polymerases that have altered fidelity of DNAsynthesis as well as to the resultant polymerase compositions. Asdisclosed herein, the invention provides rapid and efficient methods toidentify polymerase mutants having altered fidelity. These methods areapplicable to the identification of polymerase mutants having a desiredactivity such as high fidelity or low fidelity. An advantage of themethods is that they use a population of polymerase mutants to rapidlyidentify active polymerase mutants having altered fidelity. Theidentification of low fidelity mutants is useful for introducingmutations into specific genes due to the increased frequency ofmisincorporation of nucleotides during error-prone PCR amplification.The identification of high fidelity mutants is useful for PCRamplification of genes and for mapping of genetic mutations. The methodsof the invention can therefore be advantageously applied to theidentification of polymerase mutants useful for the characterization ofspecific genes and for the identification and diagnosis of human geneticdiseases.

[0017] As used herein, the term “polymerase” is intended to refer to anenzyme that polymerizes nucleoside triphosphates. Polymerases use atemplate nucleic acid strand to synthesize a complementary nucleic acidstrand. The template strand and synthesized nucleic acid strand canindependently be either DNA or RNA. Polymerases can include, forexample, DNA polymerases such as Escherichia coli DNA polymerase I andThermus aquaticus (Taq) DNA polymerase I, DNA-dependent RNA polymerasesand reverse transcriptases. The polymerase is a polypeptide or proteincontaining sufficient amino acids to carry out a desired enzymaticfunction of the polymerase. The polymerase need not contain all of theamino acids found in the native enzyme but only those which aresufficient to allow the polymerase to carry out a desired catalyticactivity. Catalytic activities include, for example, 5′-3′polymerization, 5′-3′ exonuclease and 3′-5′ exonuclease activities.

[0018] As used herein, the term “polymerase mutant” is intended to referto a polymerase that contains one or more amino acids that differ from aselected polymerase. The selected polymerase is determined based ondesired enzymatic properties and is used as a parent polymerase togenerate a population of polymerase mutants. A selected polymerase canbe, for example, a wild type polymerase as isolated from an organism orcan be a mutant polymerase that differs from a wild type polymerase byone or more amino acids and has desirable enzymatic properties. Asdisclosed herein, a thermostable polymerase such as Taq DNA polymerase Ican be selected, for example, as a polymerase to generate a populationof polymerase mutants.

[0019] As used herein, the term “population” is intended to refer to agroup of two or more different molecular species. Molecular speciesdiffer by some detectable property such as a difference in at least oneamino acid residue or at least one nucleotide residue or a differenceintroduced by the modification of an amino acid such as the addition ofa chemical functional group. For example, a population of polymerasemutants would contain two or more different polymerase mutants.Typically, populations can be as small as two species and as large as10¹² species. In some embodiments, populations are between about fiveand 20 different species as well as up to hundreds or thousands ofdifferent species. In other embodiments, populations can be, forexample, greater than 10⁴, 10⁵ and 10⁶ different species. In thespecific example presented in Example I, the population describedtherein is 50,000 different species. In yet other embodiments,populations are between about 10⁶-10⁸ or more different species. Thoseskilled in the art will know a suitable size and diversity of apopulation sufficient for a particular application.

[0020] A population of polymerase mutants consists of two or more mutantpolymerases which differ by at least one amino acid from the parentpolymerase. A population of polymerase mutants can consist, for example,of multiple substitutions of a single amino acid residue where thesubstitutions are changes to any or all of the non-parental, naturallyoccurring amino acids at that amino acid position. In this example, thepopulation would comprise nineteen members, and all members of thepolymerase mutant population would consist of nineteen different aminoacid substitutions at a single amino acid position. A population ofpolymerase mutants can also consist, for example, of at least onesubstitution at two or more different amino acid positions. In thisexample, a minimal population containing two polymerase mutants wouldconsist of a single amino acid substitution at two different positions.Such a population can be expanded with the addition of substitutions toany or all of the 19 non-parental amino acids at these two amino acidpositions or additional amino acid positions.

[0021] As used herein, the term “random” when used in reference to apopulation is intended to refer to a population of molecules generatedwithout limiting the molecules to contain predetermined specificresidues. Such a population excludes molecules in which a specificresidue is substituted with a specific predetermined residue andindividually assayed to determine its activity. The residues can beamino acid residues or nucleotide residues encoding a codon. The randommolecules can be generated, for example, by introducing randomnucleotides into an oligonucleotide sequence that encodes an amino acidsequence of a protein region of interest (see Example I). Thus, a randompopulation is generated to contain random oligonucleotide sequenceswhich can be expressed in appropriate cells to generate a randompopulation of expressed proteins. A specific example of such a randompopulation is the population of polymerase mutants described in ExampleI that were generated to screen for active polymerase mutants havingaltered fidelity.

[0022] As used herein, the term “catalytic activity” or “activity” whenused in reference to a polymerase is intended to refer to the enzymaticproperties of the polymerase. The catalytic activity includes, forexample: enzymatic properties such as the rate of synthesis of nucleicacid polymers; the K_(m) for substrates such as nucleoside triphosphatesand template strand; the fidelity of template-directed incorporation ofnucleotides, where the frequency of incorporation of non-complementarynucleotides is compared to that of complementary nucleotides;processivity, the number of nucleotides synthesized by a polymeraseprior to dissociation from the DNA template; discrimination of theribose sugar; and stability, for example, at elevated temperatures.Polymerases can discriminate between templates, for example, DNApolymerases generally use DNA templates and RNA polymerases generallyuse RNA templates, whereas reverse transcriptases use both RNA and DNAtemplates. DNA polymerases also discriminate between deoxyribonucleosidetriphosphates and dideoxyribonucleoside triphosphates. Any of thesedistinct enzymatic properties can be included in the meaning of the termcatalytic activity, including any single property, any combination ofproperties or all of the properties. Although specific embodimentsidentifying polymerase mutants having altered fidelity are exemplifiedherein, the methods of the invention can similarly be applied toidentify polymerases having altered catalytic activity distinct fromaltered fidelity.

[0023] As used herein, the term “fidelity” when used in reference to apolymerase is intended to refer to the accuracy of template-directedincorporation of complementary bases in a synthesized DNA strandrelative to the template strand. Fidelity is measured based on thefrequency of incorporation of incorrect bases in the newly synthesizednucleic acid strand. The incorporation of incorrect bases can result inpoint mutations, insertions or deletions. Fidelity can be calculatedaccording to the procedures described in Tindall and Kunkel(Biochemistry 27:6008-6013 (1988)). Methods for determining fidelity arewell known in the art and include, for example, those described inExample III. A polymerase or polymerase mutant can exhibit either highfidelity or low fidelity. As used herein, the term “high fidelity” isintended to mean a frequency of accurate base incorporation that exceedsa predetermined value. Similarly, the term “low fidelity” is intended tomean a frequency of accurate base incorporation that is lower than apredetermined value. The predetermined value can be, for example, adesired frequency of accurate base incorporation or the fidelity of aknown polymerase.

[0024] As used herein, the term “altered fidelity” refers to thefidelity of a polymerase mutant that differs from the fidelity of theselected parent polymerase from which the polymerase mutant is derived.The altered fidelity can either be higher or lower than the fidelity ofthe selected parent polymerase. Thus, polymerase mutants with alteredfidelity can be classified as high fidelity polymerases or low fidelitypolymerases. Altered fidelity can be determined by assaying the parentand mutant polymerase and comparing their activities using any assaythat measures the accuracy of template directed incorporation ofcomplementary bases. Such methods for measuring fidelity include, forexample, those described in Example III as well as other methods knownto those skilled in the art.

[0025] As used herein, the term “immutable” when used in reference to anamino acid residue is intended to refer to an amino acid residue whichcannot be substituted with another amino acid residue and still retainmeasurable function of the polypeptide. An immutable amino acid residuecan be determined by introducing one or more substitutions of an aminoacid residue and assaying the resulting mutant polypeptides forpolypeptide function. An immutable residue can be identified, forexample, using site-directed mutagenesis to substitute each of the 19non-parental amino acids at a given position and determining if any ofthese mutants are active. Random mutagenesis can also be employed tointroduce substitutions of each of the nineteen, naturally occurringnon-parental amino acids at a given position. Random mutagenesis canprovide a statistical representation of all 20 amino acids at a givenposition. Sequencing of polymerase-mutants allows determination ofwhether a given amino acid residue can tolerate any mutations. Assaysfor determining the function of mutant polypeptides include in vitroenzymatic assays as well as genetic complementation assays such as thosedescribed in Example I. If substitution of an amino acid residue withany other amino acid results in loss of polypeptide function, then thatamino acid residue is considered to be immutable.

[0026] As used herein, the term “nearly immutable” when used inreference to an amino acid residue is intended to refer to an amino acidresidue which can only tolerate conservative substitutions and stillretain polypeptide function. Conservative amino acids are known to thoseskilled in the art and include those amino acids which have similarstructure and chemical properties. Conservative substitutions of aminoacids include, for example, the identification of amino acidsubstitutions based on the frequencies of amino acid changes betweencorresponding proteins of homologous organisms (Schulz and Schirmer,Principles of Protein Structure, Springer Verlag, New York (1979)).

[0027] As used herein, the term “substantially” or “substantially thesame” when used in reference to a nucleotide or amino acid sequence isintended to mean that the function of the polypeptide encoded by thenucleotide or amino acid sequence is essentially the same as thereferenced parental nucleotide or amino acid sequence. For example,changes in a nucleotide or amino acid sequence that results insubstitution of amino acids that differ from the parent molecule butthat do not alter the desired activity of the encoded polypeptide wouldresult in substantially the same sequence. A nucleotide or amino acidsequence is substantially the same if the difference in that sequencefrom the reference parental sequence does not result in any measurabledifference in the desired activity of the encoded polypeptide.

[0028] The invention provides a method for identifying a thermostablepolymerase having altered fidelity. The method consists of generating arandom population of polymerase mutants by mutating at least one aminoacid residue of a thermostable polymerase and screening the populationfor one or more active polymerase mutants by genetic selection.

[0029] The generation and identification of polymerases having alteredfidelity or altered catalytic activity is accomplished by first creatinga population of mutant polymerases through random sequence mutagenesisof regions within the polymerase that can influence the fidelity ofpolymerization (Loeb, L. A., Adv. Pharmacol. 35:321-347 (1996)). Theidentification of active mutants is performed in vivo and is based ongenetic complementation of conditional polymerase mutants undernon-permissive conditions. Once identified, the active polymerases arethen screened for fidelity of polynucleotide synthesis.

[0030] The methods of the invention employ a population of polymerasemutants and the screening of the polymerase mutant population toidentify an active polymerase mutant. Using a population of polymerasemutants is advantageous in that a number of amino acid substitutionsincluding single amino acid and multiple amino acid substitutions can beexamined for their effect on polymerase fidelity. The use of apopulation of polymerase mutants increases the probability ofidentifying a polymerase mutant having a desired fidelity.

[0031] Screening a population of polymerase mutants has the additionaladvantage of alleviating the need to make predictions about the effectof specific amino acid substitutions on the activity of the polymerase.The substitution of single amino acids has limited predictability as toits effect on enzymatic activity and the effect of multiple amino acidsubstitutions is virtually unpredictable. The methods of the inventionallow for screening a large number of polymerase mutants which caninclude single amino acid substitutions and multiple amino acidsubstitutions. In addition, using screening methods that select foractive polymerase mutants has the additional advantage of eliminatinginactive mutants that could complicate screening procedures that requirepurification of polymerase mutants to determine activity.

[0032] Moreover, the methods of the invention allow for targeting ofamino acid residues adjacent to immutable or nearly immutable amino acidresidues. Immutable or nearly immutable amino acid residues are residuesrequired for activity, and those immutable residues located in theactive site provide critical residues for polymerase activity. Mutatingamino acid residues adjacent to these required residues provides thegreatest likelihood of modulating the activity of the polymerase.Introducing random mutations at these sites increases the probability ofidentifying a mutant polymerase having a desired alteration in activitysuch as altered fidelity.

[0033] A polymerase is selected as a parent polymerase to introducemutations for generating a library of mutants. Polymerases obtained fromthermophlic organisms such as Thermus aquaticus have particularlydesirable enzymatic characteristics due to their stability and activityat high temperatures. Thermostable polymerases are stable and retainactivity at temperatures greater than about 37° C., generally greaterthan about 50° C., and particularly greater than about 90° C. The use ofthe thermostable polymerase Taq DNA polymerase I as a parent polymeraseto generate polymerase mutants is disclosed herein (see Example I).

[0034] Although a specific embodiment using Taq DNA polymerase I isdisclosed in the examples, the methods of the invention can similarly beapplied to other thermostable polymerases other than Thermus aquaticusDNA polymerases. Such other polymerases include, for example, RNApolymerases from Thermus aquaticus and RNA and DNA polymerases fromother thermostable bacteria. Using the guidance provided herein inreference to DNA polymerases, those skilled in the art can apply theteachings of the invention to the generation and identification of theseother polymerases having altered fidelity of polynucleotide synthesis.

[0035] In addition to creating mutant DNA polymerases from organismsthat grow at elevated temperatures, the methods of the invention cansimilarly be applied to non-thermostable polymerases provided that thereis a selection or screen such as the genetic complementation of aconditional polymerase mutation as described herein (see Example I).Such a selection or screen of a non-thermostable polymerase can be, forexample, the inducible or repressible-expression of an endogenouspolymerase. Polymerases having altered fidelity can similarly begenerated and selected from both prokaryotic and eukaryotic cells aswell as viruses. Those skilled in the art will know how to apply theteachings described herein to the generation of polymerases havingaltered fidelity from such other organisms and such other cell types.

[0036] Thus, the invention provides a general method for the productionof a polymerase that has an altered fidelity in DNA or RNA synthesis.The method consists of producing a population of sufficient size anddiversity so as to contain at least one polymerase molecule having analtered fidelity and then screening that population to identify thepolymerase having altered fidelity. The altered polymerase fidelity canbe either an increase or decrease in the accuracy of DNA synthesis.

[0037] In one embodiment, the invention involves the production of arelatively large population of randomly mutagenized nucleic acidsencoding a polymerase and introduction of the population into host cellsto produce a library. The mutagenized polymerase encoding nucleic acidsare expressed, and the library is screened for active polymerase mutantsby complementation of a temperature sensitive mutation of an endogenouspolymerase. Colonies which are viable at the non-permissive temperatureare those which have polymerase encoding nucleic acids which code foractive mutants.

[0038] To generate a random population of polymerase mutants, a randomsequence of nucleotides is substituted for a defined target sequence ofa plasmid-encoded gene that specifies a biologically active molecule. Inone application of this procedure, a double-strandedoligodeoxyribonucleotide is provided by hybridizing two partiallycomplementary oligonucleotides, one or both of which contain randomsequences at specified positions. The partially double-strandedoligonucleotide is filled in by DNA polymerase, cut at restriction sitesand ligated into a DNA vector. The plasmid encodes the gene for athermostable DNA polymerase, and the oligonucleotide is inserted inplace of a portion of the gene that modulates the fidelity of DNAsynthesis. After ligation, the reconstructed plasmids constitute alibrary of different nucleic acid sequences encoding the thermostableDNA polymerase and polymerase mutants.

[0039] As disclosed herein, a genetic screen can be used to identifyactive polymerase mutants having altered fidelity. The library ofnucleic acid sequences encoding polymerase and polymerase mutants aretransfected into a bacterial strain such as E. coli strain recA718polA12, which contains a temperature sensitive mutation in DNApolymerase. Exogenous DNA polymerases have been shown to functionallysubstitute for E. coli DNA polymerase I using E. coli strain recA718polA12 and to complement the observed growth defect at elevatedtemperature, presumably caused by the instability of the endogenous DNApolymerase I at elevated temperatures (Sweasy and Loeb, J. Biol. Chem.267:1407-1410 (1992); Kim and Loeb, Proc. Natl. Acad. Sci USA 92:684-688(1995)). It was unknown, however, whether a thermostable polymerasecould substitute for E. coli DNA polymerase given the distinct and harshenvironment experienced by thermophilic organisms in which enzymes mustfunction at extremely high temperatures. As disclosed herein, wild typeTaq DNA polymerase I was found to complement the growth defect of E.coli strain-recA718 polA12 (see Example I). Using such a complementationsystem, various mutant Taq DNA polymerase I mutants were identified inhost bacteria that harbor plasmids encoding active thermoresistant DNApolymerases that allowed bacterial growth and colony formation atelevated (restrictive) temperatures (see Examples I and II).

[0040] The invention also provides a method for identifying athermostable polymerase having altered fidelity. The method consists ofgenerating a random population of polymerase mutants by mutating atleast one amino acid residue in an active site O-helix of a thermostablepolymerase and screening the population for one or more activepolymerase mutants.

[0041] The invention additionally provides a method for identifying athermostable polymerase having altered catalytic activity. The methodconsists of generating a random population of polymerase mutants bymutating at least one amino acid residue of a thermostable polymeraseand screening the population for one or more active polymerase mutants.

[0042] A random population of polymerase mutants is generated bymutating one or more amino acid residues in an active site O-helixtarget sequence of a thermostable polymerase. The O-helix has beenpostulated to interact with the substrate template complex (Joyce andSteitz, supra, (1994)). The O-helix has been observed in the crystalstructure of E. coli DNA polymerase I Klenow fragment and Taq DNApolymerase (Beese et al., Science 260:352-355 (1993); Kim et al., Nature376:612-616 (1995)). As disclosed in Example II, random sequences weresubstituted for nucleotides encoding amino acids Arg659 through Tyr671of the O-helix of Taq DNA polymerase I to generate a random populationof polymerase mutants.

[0043] Using a genetic complementation screen, a variety of active TaqDNA polymerase I mutants were identified (see Example II). Several aminoacid residues were found to be immutable or nearly immutable based onthe complementation assay. These immutable or nearly immutable aminoacid residues in the O-helix are Arg659, Lys663, Phe667 and Tyr671. Asused herein, a wild type amino acid is designated as a residue precedingthe number of the amino acid position. A mutated amino acid isdesignated as a residue following the number of the amino acid position.These immutable or nearly immutable sites are unable to be altered andstill maintain the function of the DNA polymerase. Due to their positionin the active site O-helix of Taq DNA polymerase I, these immutable ornearly immutable residues provide critical residues that are requiredfor the activity of the polymerase.

[0044] In addition to the O-helix of a polymerase, other regions of thepolymerase can be targeted for random mutagenesis to generate a libraryof polymerase mutants to identify polymerase mutants having alteredfidelity. Those skilled in the art can determine other regions to targetfor mutagenesis. Such other regions can be identified, for example, bysequence homology to other polymerases, which suggests conservation offunction. Conserved sequences can also be used to identify targetregions for mutagenesis based on activity studies of other polymerases.Protein structural models revealing the convergence of amino acidresidues at the active site of a polymerase can similarly be used toidentify target regions for mutagenesis.

[0045] Alternatively, mutagenesis throughout the polymerase can be usedto identify amino acid residues critical for polymerase function.Sequences containing these critical amino acid residues are targetsequences for introducing random mutations to identify mutants havingaltered fidelity. Methods for identifying critical amino acid residuesby introducing a small number of random mutations throughout a genesegment are well known to those skilled in the art and include, forexample, copying by mutagenic polymerases, exposure of templates to DNAdamaging agents prior to inserting into cells and replacement of regionsof the DNA template with oligonucleotides containing sparsely populatedrandom inserts. For example, a population of oligonucleotides with 91%correct substitutions and 3% of the non-complementary nucleotides ateach position can be generated. Screening for polymerase mutants can beperformed, for example, with the genetic complementation assay disclosedherein.

[0046] The invention also provides a method for identifying athermostable polymerase having altered fidelity. The method consists ofgenerating a random population of polymerase mutants by mutating one ormore amino acid residues adjacent to an immutable or nearly immutableresidue in an active site O-helix of a thermostable polymerase andscreening the population for one or more active polymerase mutants.

[0047] In one embodiment, substitutions at amino acids adjacent toimmutable or nearly immutable residues are used to identify polymerasemutants having altered fidelity. The adjacent amino acid residues can beimmediately adjacent in the linear sequence or can be nearby. Adjacentresidues that are nearby can be as many as two amino acids away from theimmutable or nearly immutable residue in the linear sequence. A nearbyresidue can also be nearby in the three-dimensional structure of thepolymerase and can be determined from a crystallographic molecular modelof a polymerase. Nearby residues are in close enough proximity to animmutable or nearly immutable residue to modulate the activity of thepolymerase. Generally, nearby residues are within two amino acidresidues in the linear sequence from an immutable or nearly immutableresidue or are within about 5 Å of the immutable or nearly immutableresidues, in particular within about 3 Å.

[0048] Substitutions involving amino acid residues adjacent to immutableor nearly immutable sites have been found to alter the fidelity of DNAsynthesis (see Examples IV and V). The identified immutable or nearlyimmutable amino acid residues correspond to amino acid residues Arg659,Lys663, Phe667 and Tyr671 of Taq DNA polymerase I. Thus, the inventionis directed to altering one or more amino acid residues adjacent to anamino acid residue corresponding to Arg659, Lys663, Phe667 or Tyr671 inTaq DNA polymerase. Amino acid residues adjacent to these immutableresidues include, for example, amino acids corresponding to Arg660,Ala661, Ala662, Thr664, Ile665, Asn666, Gly668, Val669 and Leu670 in TaqDNA polymerase I. Corresponding residues in other polymerases are alsoincluded and can be identified based on sequence homology or based oncorresponding amino acids in structurally similar domains as defined bya crystallographic molecular model.

[0049] The methods of the invention are also directed to alteringresidues immediately adjacent to the immutable or nearly immutableresidues. Thus, the methods of the invention are directed to alteringresidues adjacent to required residues on DNA polymerases andidentifying those mutations which have an effect on the fidelity of DNAsynthesis.

[0050] The invention further provides methods for determining a fidelityof the active polymerase mutant. The fidelity of active polymerasemutants can be determined by several methods. The active polymerases canbe, for example, screened for altered fidelity from crude extracts ofbacterial cells grown from the viable colonies. Methods for determiningfidelity of synthesis are disclosed herein (see Example III). In onemethod, a primer extension assay is used with a biased ratio ofnucleoside triphosphates consisting of only three of the nucleosidetriphosphates. Elongation of the primer past template positions that arecomplementary to the deleted nucleoside triphosphate substrate in thereaction mixture results from errors in DNA synthesis. Processivity ofhigh fidelity polymerases will terminate when they encounter a templatenucleotide complementary to the missing nucleoside triphosphate whereasthe low fidelity polymerases will be more likely to misincorporate anon-complementary nucleotide. The accuracy of incorporation for theprimer extension assay can be measured by physical criteria such as bydetermining the size or the sequence of the extension product. Thismethod is particularly suitable for screening for low fidelity mutantssince increases in chain elongation are easily and rapidly quantitated.

[0051] A second method for determining the fidelity of polymerasemutants employs a forward mutation assay. A template containing a singlestranded gap in a reporter gene such as lacZ is used for the forwardmutation assay. Filling in of the gapped segment is carried out by crudeheat denatured bacterial extracts harboring plasmids expressing athermostable DNA polymerase mutant. For determining low fidelitypolymerase mutants, reactions are carried out in the presence ofequimolar concentrations of each nucleoside triphosphate. Fordetermining high fidelity polymerase mutants, the reaction is carriedout with a biased pool of nucleoside triphosphates. Using a biased poolof nucleoside triphosphates results in incorporation of errors in thesynthesized strand that are proportional to the ratio ofnon-complementary to complementary nucleoside triphosphates in thereaction. Therefore, the bias exaggerates the errors produced by thepolymerases and facilitates the identification of high fidelity mutants.The fidelity of DNA synthesis is determined from the number of mutationsproduced in the reporter gene.

[0052] Procedures other than those described above for identifying andcharacterizing the fidelity of a polymerase are known in the art and canbe substituted for identifying high or low fidelity mutants. Thoseskilled in the art can determine which procedures are appropriatedepending on the needs of a particular application.

[0053] Also provided herein is an isolated thermostable polymerasemutant having altered fidelity. The polymerase mutant has one or moremutated amino acid residues in the active site O-helix of a thermostablepolymerase. Additionally provided is an isolated thermostable polymerasemutant having altered fidelity. The polymerase mutant has one or moremutated amino acid residues adjacent to an immutable or nearly immutableamino acid residue in the active site O-helix of a thermostablepolymerase. The mutated amino acid residue is adjacent to an amino acidresidue corresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNApolymerase.

[0054] The invention also provides an isolated thermostable polymerasemutant having altered fidelity, where the polymerase has one or moremutated amino acid residues adjacent to an amino acid residuecorresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNA polymeraseand the mutant is a high fidelity mutant.

[0055] Using the methods of the invention, a number of mutants have beenidentified as having high fidelity of DNA synthesis. For example,polymerases having one or more single-base substitutions adjacent toArg659, Lys663, Phe667, and Tyr671 in the nucleotide sequence of Taq DNApolymerase I have been identified. Specific examples of these highfidelity mutants include, for example, polymerases having the singlesubstitutions Asn666Asp, Asn666Ile, Ile665Leu, Leu670Val, Arg660TyrArg660Ser, Gly668Arg, Arg660Lys, Gly668Ser and Gly668Gln; polymeraseshaving the double substitutions consisting of Thr664Ile together withAsn666Asp, and Ala661Ser together with Val669Leu; as well as polymeraseshaving the triple substitutions consisting of Thr664Pro, Ile665Valtogether with Asn666Tyr, and Ala661Glu, Ile665Thr together withPhe667Leu. Additional high fidelity mutants include, for example,Phe667Leu and Phe667Tyr.

[0056] The invention provides a high fidelity polymerase mutant havingone or more amino acid substitutions selected from the group consistingof Phe667Leu; Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr;Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile andAsn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu;and Thr664Pro, Ile665Val and Asn666Tyr. The polymerase mutant Phe667Tyrhas been previously described and is excluded from the compositions ofthe invention.

[0057] The invention also provides an isolated thermostable polymerasemutant having altered fidelity, where the polymerase has one or moremutated amino acid residues adjacent to an amino acid residuecorresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNA polymeraseand the mutant is a low fidelity mutant. The invention additionallyprovides a low fidelity polymerase mutant having one or more amino acidsubstitutions selected from the group consisting of Ala661Glu;Ala661Pro; Thr664Pro; Thr664Asn; Thr664Arg; Asn666Val; Thr664Pro andVal669Ile; Arg660Pro and Leu670Thr; Arg660Trp and Thr664Lys; Ala662Glyand Thr664Asn; Ala661Gly and Asn666Ile; Ala661Pro and Asn666Ile; andAla661Ser, Ala662Gly, Thr664Ser and Asn666Ile.

[0058] Low fidelity mutant DNA polymerases include mutations involvingsubstitutions at Ala661, Thr664, Asn666, and Leu670. Specific examplesof low fidelity mutants include, for example, polymerases having thesingle substitutions Ala661Glu, Ala661Pro, Thr664Pro, Thr664Asn,Thr664Arg and Asn666Val; polymerases having the double substitutionsconsisting of Thr664Pro together with Val669Ile, Arg660Pro together withLeu670Thr, Arg660Trp together with Thr664Lys, Ala664Gly together withThr664Asn, Ala661Gly together with Asn666Ile, and Ala661Pro togetherwith Asn666Ile; as well as polymerases having four substitutionsconsisting of Ala661Ser, Ala662Gly, Thr664Ser together with Asn666Ile.

[0059] For both the high fidelity and the low fidelity mutationsdescribed above, the invention provides polymerases other than Taq DNApolymerase having mutations at corresponding positions. In particular,the invention provides thermostable polymerases other than Taq DNApolymerase that have mutations at corresponding positions and that havealtered fidelity. Those skilled in the art can determine correspondingpositions based on sequence homology between the polymerases.

[0060] The invention also provides an isolated nucleic acid moleculeencoding a polymerase mutant having high fidelity. The nucleic acidmolecule contains a nucleotide sequence encoding substantially an aminoacid sequence of Taq DNA polymerase I having one or more amino acidsubstitutions selected from the group consisting of Phe667Leu;Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr; Phe667Tyr;Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile andAsn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu;and Thr664Pro, Ile665Val and Asn666Tyr.

[0061] Additionally provided is an isolated nucleic acid moleculeencoding a polymerase mutant having low fidelity. The nucleic acidmolecule contains a nucleotide sequence encoding substantially an aminoacid sequence of Taq DNA polymerase I having a substitution of one ormore amino acids selected from the group consisting of Ala661, Thr664,Asn666 and Leu670. The invention also provides a polymerase mutanthaving one or more amino acid substitutions selected from the groupconsisting of Ala661Glu; Ala661Pro; Thr664Pro; Thr664Asn; Thr664Arg;Asn666Val; Thr664Pro and Val669Ile; Arg660Pro and Leu670Thr; Arg660Trpand Thr664Lys; Ala664Gly and Thr664Asn; Ala661Gly and Asn666Ile;Ala661Pro and Asn666Ile; and Ala661Ser, Ala662Gly, Thr664Ser andAsn666Ile.

[0062] The invention also provides methods for the identification of oneor more mutations in a gene using the high fidelity mutant DNApolymerases of the invention. For example, the use of a high fidelitymutant to amplify a gene of interest gives greater confidence that theamplified sequence will more accurately reflect the actual sequence inthe sample and minimizes the introduction of artifactual mutationsduring amplification of the gene. The higher accuracy of geneamplification provided by a high fidelity mutant also improves theidentification of genetic mutations due to the increased confidence thatobserved mutations are more likely to reflect genetic mutations in thesample rather than artifactual mutations introduced duringamplification.

[0063] Additionally, the invention provides methods for identifying oneor more mutations in a gene by amplifying the gene using a high fidelitypolymerase mutant under conditions which allow polymerase chain reactionamplification. The gene is amplified by exposing the strands of the geneto repeated cycles of denaturing, annealing and elongation to produce anamplified gene product. Methods for amplifying genes using PCR are wellknown to those skilled in the art and include those described previouslyin PCR Primer. A Laboratory Manual, Dieffenbach and Dveksler, eds., ColdSpring Harbor Press, Plainview, N.Y. (1995). The presence or absence ofone or more mutations in the gene can be determined by sequencing theamplified product using methods well known to those skilled in the art.

[0064] The invention provides methods for accurately copying repetitivenucleotide sequences by amplifying the repetitive nucleotide sequenceusing a high fidelity polymerase mutant. The repetitive nucleotidesequence can be in a gene or in a microsatellite between genes. Themethods of amplifying the repetitive nucleotide sequences are carriedout under conditions which allow PCR amplification with repeated cyclesof denaturing, annealing and elongation as described above.

[0065] The high fidelity mutants of the invention are advantageous forcopying repetitive nucleotide sequences such as repetitive DNA becausepolymerases found in nature undergo slippage when copying DNA containingrepetitive sequences. Therefore when polymerases found in nature areused, the amplification products of a nucleotide sequence containing arepetitive sequence do not accurately reflect the size or sequence of aDNA sequence in a sample. However, the use of a high fidelity polymerasemutant greatly increases the accuracy of an amplification product toreflect the actual size and sequence of the repetitive DNA sequence inthe sample. Repetitive DNA can be found in microsatellites, whichcontain multiple repetitive nucleotide sequences and are dispersedthroughout the genome. These repetitive di-, tri- and tetranucleotidesare frequently, but not invariably, located between genes.

[0066] The invention also provides a method for determining an inheritedmutation by amplifying a gene using a high fidelity polymerase mutant.Such an inherited mutation can be correlated with a genetic disease,thereby allowing diagnosis of the genetic disease. The inventionadditionally provides methods for diagnosing a genetic disease byamplifying a gene using a high fidelity polymerase mutant. A geneticdisease is one in which a disease is caused by a genetic mutation in acoding or non-coding region of DNA. Such a genetic mutation can be asomatic mutation or a germline mutation. The methods of the inventioncan be used to diagnose any genetic disease using high fidelitypolymerase mutants. Such genetic diseases can involve point mutations,insertions and deletions.

[0067] The methods of the invention employ high fidelity polymerasemutants and can similarly be used to diagnose genetic diseases involvingrepetitive DNA. In one embodiment, the genetic disease involvesmutations in a microsatellite or repetitive DNA. Microsatellites arerelatively stable in normal cells but are found to be unstable and tovary in length in some forms of hereditary and non-hereditary cancer,including hereditary nonpolyposis colorectal cancer (HNPCC), othercancers that arise in HNPCC families, Muir-Torre syndrome and small-celllung cancer (Loeb, Cancer Res. 54:5059-5063 (1994); Brentnall, Am. J.Pathol. 147:561-563 (1995); Honchel et al., Semin. Cell Biol. 6:45-52(1995); Eshleman and Markowitz, Curr. Opin. Oncol. 7:83-89 (1995)).Microsatellite instability appears to be confined to tumors and is notpresent in normal tissues of affected individuals.

[0068] The accuracy of amplification products of repetitive DNAsequences provided by the high fidelity mutants of the invention can beused to diagnose diseases involving mutations in repetitive DNAsequences. For example, with tumor samples, the accurate amplificationof repetitive DNA sequences can be used to diagnose those cancersinvolving variable length in microsatellite DNA. Since microsatelliteinstability appears to be confined to tumors, amplification ofrepetitive DNA using the high fidelity mutants of the invention canadditionally be applied to determining the prognosis or extent ofdisease of a cancer patient, evaluating outcomes of therapy, stagingtumors and determining tumor status. High fidelity mutants of theinvention can also be applied to amplify DNA in blood samples toidentify circulating cells containing microsatellite instability as anindicator of a cancerous state.

[0069] Other genetic diseases also involve repetitive DNA sequences, inparticular, unstable triplet repeats. These unstable triplet repeatdiseases involve increasing lengths of triplet repeat regions, rangingfrom ˜50 repeats in normal individuals, ˜200 repeats in carriers to˜2000 repeats in affected individuals. Such unstable triplet repeatdiseases include, for example, fragile X syndrome, spinal and bulbarmuscular atrophy, myotonic dystrophy, Huntington's disease,spinocereballar ataxia type 1, fragile X E mild mental retardation anddentatorubral pallidoluysian atrophy (Monckton and Caskey, Circulation91:513-520 (1995)). The diagnosis of unstable triplet repeat diseases isparticularly valuable since the onset of symptoms can occur later insome diseases and the severity of the symptoms of some diseases can becorrelated with the size of the extended triplet repeat region. Thus,amplification of these triplet repeat regions to more accurately reflectthe actual size of the triplet repeat in the individual provides moreaccurate diagnosis and prognosis of the disease. Amplification of thelarge expanded regions associated with triplet repeat diseases can becarried out using low fidelity polymerase mutants of the invention sincelow fidelity polymerase mutants would be more likely to copy throughvery long stretches of repetitive nucleotide sequences.

[0070] One method for identifying a genetic disease involves utilizationof primers that hybridize to specific genes. The primers contain3′-terminal nucleotides complementary to the corresponding nucleotide inthe mutant but not to the wild type gene. The mismatched primer is usedto extend the primer template in the presence of a high fidelity mutantpolymerase. The presence of an extension product is indicative of amutant gene.

[0071] The mismatch PCR method is based on the fact that a PCR primerthat is not complementary to the template at the 3′ end is aninefficient substrate for polymerases such as Taq DNA polymerase I. Wildtype Taq DNA polymerase will occasionally misextend a mismatched primer,resulting in a false positive in an assay for a gene mutation. Forexample, a mutant gene with a rare TT mutation would be difficult tospecifically amplify out of a pool of DNA molecules containing a wildtype CC at the position of the TT mutant because wild type Taq DNApolymerase would occasionally misextend the wild type gene using themismatched primer. In contrast, a high fidelity polymerase would notextend the mismatched primer. The products of a high fidelity polymerasein the mismatch PCR assay would therefore correspond to the mutant geneand would have fewer false positives than that observed with wild typeTaq DNA polymerase. Thus, the more discriminating assay based on the useof high fidelity polymerases results in a better assay for detectingsomatic mutations. The use of high fidelity mutants in such amismatch-PCR based assay is disclosed herein (see Example V).

[0072] The invention also provides a method for randomly mutagenizing agene by amplifying the gene using the low fidelity polymerase mutants ofthe invention. The low fidelity polymerase mutants exhibit an efficiencyof accurate base incorporation that is less than that of wild typepolymerases. The efficiency of the low fidelity polymerase mutant isabout 50% or more, generally 10% or more, and particularly 1% or morethan that of a wild type polymerase. These low fidelity polymerasemutants would therefore exhibit between 2-fold to 100-fold lowerfidelity than wild type polymerase. The introduction of mutations intospecific genes using low fidelity polymerase mutants of the invention isuseful for determining the effects of mutations on the function of thosegene products.

[0073] It is understood that modifications which do not substantiallyaffect the activity of the various embodiments of this invention arealso included within the definition of the invention provided herein.Accordingly, the following examples are intended to illustrate but notlimit the present invention.

EXAMPLE I Random Sequence Mutagenesis and Identification of Active TaqDNA Polymerase Mutants

[0074] This example demonstrates random nucleotide sequence mutagenesisof a polymerase target sequence and identification of active polymerasemutants.

[0075] Random sequence mutagenesis was used to introduce mutations intothe O-helix of Taq DNA polymerase. Briefly, the Taq DNA polymerase Igene was obtained from the bacterial chromosome by cloning in pKK223-3(Pharmacia Biotech, Piscataway, N.J.). A 3.2-kb fragment containing theTaq DNA polymerase I gene, including the 5′-3′ exonuclease domain andthe tac promoter region, was further transferred into the SalI site ofpHSG576 (pTacTaq). The Taq DNA polymerase I gene was sequenced toconfirm wild type sequence except for the lack of the N-terminal threeamino acids.

[0076] A vector containing a nonfunctional insert within the Taq DNApolymerase I gene was constructed and subsequently replaced with anoligonucleotide containing the random sequence to avoid contaminationwith incompletely cut vectors. To generate the nonfunctional vector, aSacII site was produced using site-directed mutagenesis by changing2070C to G using a synthetic oligomer, 5′-GGG TCC ACG GCC TCC CGC GGGACG CCG AAC ATC CAG CTG (SEQ ID NO:3) (SacII-2) and the single-strandedplasmid pFC85 (Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985)).The BstX1-NheI fragment that carries the SacII site was substituted forthe corresponding fragment in pTacTaq (pTacTaqSac). A SacII-NheIfragment in pTacTaqSac was further replaced with the synthetic oligomer5′-GGA CTG CAT ATG ACT G (SEQ ID NO:4) (DUM-U) hybridized with 5′-CTAGCA GTC ATA TGC AGT CCG C (SEQ ID NO:5) (DUM-D) to create thenonfunctional vector (Dube et al., Biochemistry 30:11760-11767 (1991)).

[0077] Oligonucleotides containing 9% random sequence, in which eachnucleotide indicated in parentheses was 91% wild type nucleotide and 3%each of the other three nucleotides, were synthesized by KeystoneLaboratories (Menlo Park, Calif.): O+9 RANDOM is 5′-CGG GAG GCC GTG GACCCC CTG ATG (CGC CGG GCG GCC AAG ACC ATC AAC TTC GGG GTC CTC TAC) GGCATG TCG GCC CAC CG (SEQ ID NO:6); O-0 RANDOM is 5′-TGG CTA GCT CCT GGGAGA GGC GGT GGG CCG ACA TGC C (SEQ ID NO:7). The 17 nucleotide sequencesat the 3′ ends of the two oligonucleotides are complementary. Equimolaramounts of these oligonucleotides (20 pmol) were mixed, hybridized, andextended by five cycles of PCR reaction (94° C. for 30 sec, 57° C. for30 sec, and 72° C. for 30 sec) in a 100 μl reaction mixture containing10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 50 μMdNTPs, and 2.5 units of Taq DNA polymerase I. This PCR product (10 μl)was further amplified 25 cycles with 20 pmol of O(+)PRIMER (5′-TTC GGCGTC CCG CGG GAG GCC GTG GAC CCC CT)(SEQ ID NO:8) and 20 pmol ofO(−)PRIMER (5′-GTA AGG GAT GGC TAG CTC CTG GGA)(SEQ ID NO:9) under thesame conditions. The amplified product was purified by phenol/chloroformextraction followed by ethanol precipitation and digestion with therestriction enzymes, SacII and NheI, at 37° C. for 30 min in 50 mMTris-HCl (pH 7.9), 50 mM NaCl, 10 mM MgCl₂ and 1 mM dithiothreitol. Therestriction fragment containing the random sequence was purified byphenol/chloroform extraction, ethanol precipitation, and filtrationusing a Microcon 30 filter (Amicon, Beverly, Mass.). For the totallyrandom library, five oligonucleotides (80-mers), each having totallyrandom sequence at one of the codons 659, 660, 663, 667 or 668, werecombined in equal amounts and hybridized to O-0 RANDOM. After extensionand digestion with endonucleases, the combined products were purifiedand processed as above.

[0078] A random library of Taq DNA polymerase genes containingrandomized nucleotide sequence corresponding to the O-helix wasgenerated by digesting the vector containing the nonfunctional insertwith NheI and SacII restriction endonucleases. The large DNA fragmentwas isolated by electrophoresis in a 0.8% agarose gel and purified byusing GenCleanII (Bio101, Vista, Calif.). This large fragment, lackingthe nonfunctional insert, was ligated with an oligonucleotide containingrandomized sequence by incubating overnight at 16° C. with T4 DNAligase. The ligation mixture was then used to transform DH5α byelectroporation according to Bio-Rad (Hercules, Calif.). Afterelectroporation, 1 ml of SOC (2% bactotryptone/0.5% yeast extract/10 mMNaCl/2.5 mM KCl/10 MM MgCl₂/10 mM MgSO₄/20 mM glucose) was added andincubation continued for 1 h at 37° C. An aliquot was plated on 2×YT (16g/liter tryptone, 10 g/liter yeast extract, 5 g/liter NaCl, pH 7.3)containing 30 μg/ml chloramphenicol to determine the total number oftransformants, and the remainder was inoculated into 500 ml of 2×YTcontaining 30 μg/ml chloramphenicol and cultured at 37° C. overnight.Plasmids (random library vector) were purified and used fortransformation of recA718 polA12 strain.

[0079] For genetic complementation to determine active polymerasemutants, E. coli recA719 polA12 cells (SC18-12 E. coli B/r strain, whichhas the genotype recA718 polA12 uvrA155 trpE65 lon-11 sulA1) weretransformed with plasmids pHSG576 or pTacTaq by electroporation (Bio-RadGenepulser, 2kV, 25 μFD, 400 Ω) (Sweasy and Loeb, supra, (1992); Sweasyand Loeb, Proc. Natl. Acad. Sci. USA 90:4626-4630 (1993); Witkin andRoegner-Maniscalo, J. Bacteriol. 174:4166-4168 (1992)). Thereafter, 1 mlof nutrient broth (NB) (8 g/liter) containing NaCl (4 g/liter) and 1 mMisopropyl β-D-thiogalactoside (IPTG) was added and the mixture wasincubated for 1 h at 37° C. The transformed cells were plated onnutrient agar plates (containing 23 g/liter Difco nutrient agar, 5g/liter NaCl, 30 μg/ml chloramphenicol, 12.5 μg/ml tetracycline and 1 mMIPTG) and grown at 30° C. overnight. Single colonies were transferred toNB for growth to logarithmic phase at 30° C. Thereafter, ˜10 μl (10⁴cells) was introduced at the center of an agar plate, and theinoculation loop was gradually moved from the center to the periphery asthe plate was rotated. Duplicate plates were incubated at 30° C. or 37°C. for 30 h. To determine complementation efficiency by Taq DNApolymerase I and to isolate mutants, cultures of the recA718 polA12strain harboring either pHSG576 or Taq DNA polymerase I were dilutedwith NB medium and plated (˜500 colonies per plate). Duplicate plateswere incubated at 30° C. or 37° C., and visible colonies were countedafter a 30 h incubation. Complementation was verified by a second roundof electroporation and colony formation at the nonpermissivetemperature. Cell-free extracts were prepared from selected coloniesobtained at the restrictive temperature and assayed to confirm that theycontained a temperature-resistant DNA polymerase activity (Lawyer etal., J. Biol. Chem. 264:6427-6437 (1989)).

[0080] Wild type Taq DNA polymerase I was tested for its ability tocomplement a temperature sensitive polymerase contained in the E. colistrain recA718 polA12, which is unable to grow at 37° C. in rich mediaat low cell density (Witkin and Roegner-Maniscalo, 1992, supra). Thetemperature sensitive phenotype of E. coli strain recA718 polA12 wascomplemented by transformation with the pTacTaq plasmid encoding wildtype Taq DNA polymerase I as indicated by growth at 37° C. Therefore,this E. coli strain containing a temperature sensitive polymeraseprovides a good model system for testing Taq DNA polymerase I mutants.

[0081] To evaluate the involvement of different amino acid residues incatalysis by Taq DNA polymerase I, random sequences were substituted fornucleotides encoding a portion of the substrate binding site of Taq DNApolymerase I (O-helix, amino acids Arg659 through Tyr671). Thesubstituted stretch was 39 nucleotides long with 9% randomization. Ateach position the proportion of the wild type residue was 91% and theother 3 nucleotides were present in equal amounts (3% each).

[0082] A library of 50,000 independent mutants was obtained. The numberof colonies obtained at 37° C. was 11.8% of that obtained at 30° C.Therefore, screening a randomized library using E. coli strain recA718polA12 provided approximately 5900 colonies containing active Taq DNApolymerase and potential polymerase mutants.

[0083] These results show that a randomized library can be used togenerate a population of polymerase mutants. These results also show theidentification of active Taq DNA polymerase I mutants by screening foractive polymerase mutants using genetic selection.

EXAMPLE II Identification of Taq DNA Polymerase I Mutants and Immutableor Nearly Immutable Amino Acid Residues

[0084] This example describes the identification Taq DNA polymerase Imutants generated by a randomized library and the identification ofimmutable or nearly immutable amino acid residues.

[0085] The active Taq DNA polymerase I mutants identified by the screendescribed in Example I were further characterized. The entire randomnucleotide-containing insert was sequenced from a total of 234 plasmidsobtained at 37° C. (positively selected), 16 plasmids obtained at 30° C.(nonselected) and 29 plasmids obtained at 30° C., which failed to growat 37° C. (negatively selected). All substitutions were in therandomized nucleotides except for 12 clones.

[0086] Among the 230 positive plasmids, 168 contained silent mutationsin one or more codons. At the amino acid level, 106 encoded the wildtype residue and 124 encoded substitutions, in accord with the expecteddistribution in the plasmid population. Of the 124 plasmids with aminoacid changes, 40 were unique mutants obtained just once. The remaining84 plasmids represented 21 different mutants. At least 79% of thoseencoding the same amino acid substitutions were independently derivedsince they contained different silent mutations in other codons. Intotal, 61 different amino acid sequences were obtained that complementedthe temperature-sensitive phenotype of the recA718 polA12 host.

[0087] A compilation of the amino acid substitutions found in Taq DNApolymerase I is shown in FIG. 2. Solid boxes indicate the amino acidresidues for which no substitutions were detected. Dashed boxes mark theamino acid positions where only conservative substitutions were found.The amino acid positions of Taq DNA polymerase I and correspondingpositions of E. coli DNA polymerase I are indicated at the top. WTrepresents the wild type sequence and randomized amino acids are writtenin boldface type. The amino acids that have not been found in the DNApolymerase I family are outlined (Braithwaite and Ito, Nucleic AcidsRes. 21:787-802 (1993)). Panel A shows single mutations selected fromthe 9% library listed under the wild type amino acids. Panel B shows thesequence of each multiply substituted mutant selected from the 9%library. Panel C shows mutations selected from the totally randomlibrary.

[0088] The distribution of single amino acid substitutions among theactive mutants was not random (see FIG. 2A). For example, numerousdiverse substitutions were observed at Ala661 and Thr664. In contrast,no substitutions were detected at five positions (Arg659, Arg660,Lys663, Phe667 and Gly668). This uneven distribution of replacements isunlikely to be the result of a bias in the nucleotide composition of therandom insert since sequencing of both the nonselected and negativelyselected plasmids revealed multiple nucleotide substitutions at each ofthe targeted positions and because silent mutations were detected ateach of these positions in the selected clones.

[0089] A nonrandom distribution of substitutions was also observed amongactive mutants containing multiple substitutions (see FIG. 2B). Again,Ala661 and Thr664 were replaced with a variety of residues. However, noamino acid substitutions were observed in place of Arg659, Lys663 andGly668, even though different silent nucleotide substitutions were foundat each of these positions. A comparison of FIGS. 2A and B shows thatsubstitutions at Arg660 and Phe667 occur only in the presence ofsubstitutions at other positions. In addition to the mutants containingmultiple substitutions shown in FIG. 2B, two additional triple mutantswere also found: mutant 44, with Ala661Pro, Thr664Arg, and Val669Leu;and mutant 54, with Ala661Thr, Thr664Pro and Ile665Val.

[0090] The partially substituted library (9%) does not provide avigorous test of the immutability of specific codons. Only 0.07% ofsequences at each codon would be expected to contain nucleotidesubstitutions at all three positions. To further probe the mutability ofspecific amino acid residues, a second library was constructed thatcontained totally random substitutions at a limited number of designatedcodons. In this library, nucleotides encoding each of the five aminoacids Arg659, Arg660, Lys663, Phe667 and Gly668 were randomized. Thesewere amino acid positions that did not yield single substitutions in the9% random library (FIG. 2A). Approximately 1300 transformants, which is4 times more than the number required for each possible substitution ateach of the target codons, were screened. At the nonpermissivetemperature, 113 colonies were obtained, 84 of which contained codonsthat encoded the wild type amino acid sequence. Most of the amino acidsubstitutions occurred in place of Arg660 or Gly668.

[0091] Again, Arg659 and Lys663 were completely conserved, with 16 and 5silent mutations scored at these codons, respectively. The expectednumber of silent mutations were 21 and 4.2, respectively, assuming thatthe 5 randomized oligomers that comprised the library were mixed inequimolar proportions. These numbers show that the oligomers wereroughly equally represented in the library and that sufficient mutantswere sampled to conclude that Arg659 and Lys663 are immutable in thesegenetic complementation experiments (P<0.05 for Met and Trp, P<0.01 forall other substitutions). Only Tyr substituted for Phe at position 667(FIG. 2C), and six silent mutations were scored for this codon. Anadditional mutant obtained with the totally randomized library but notshown in FIG. 2 is mutant 601, with double substitutions Ile665Asn andVal669Ile.

[0092] These results show that generating a random library and screeningby genetic complementation provided a number of active Taq DNApolymerase I mutants. These results also show that amino acid residuesArg659 and Lys663 were found to be immutable and Phe667 and Tyr671 werefound to tolerate only conservative substitutions.

EXAMPLE III Determination of the Fidelity of Active Taq DNA Polymerase IMutants

[0093] This example describes methods of determining the fidelity ofactive Taq DNA polymerase I mutants. Two types of assays are useful fordetermining the fidelity of active polymerase mutants, a primerextension assay and a forward mutation assay.

[0094] Crude extracts were used to determine the fidelity of polymerasemutants. A single colony of E. coli DH5α (F⁻, φ80dlacZΔM15,Δ(lacZYA-argF)U169, deoR, recA1, endA1, phoA, hsdR17(r_(k) ⁻m_(k) ⁺),supE44, λ⁻, thi-1, gyrA96, relA1) carrying wild type or mutant Taq DNApolymerase I was inoculated into 40 ml of 2×YT (16 g/liter tryptone, 10g/liter yeast extract, 5 g/liter NaCl, pH 7.3) containing 30 mg/literchloramphenicol. After incubation at 37° C. overnight with vigorousshaking, an equal amount of fresh medium with 0.5 mM IPTG was added, andincubation was continued for 4 h. Cells were harvested, washed once withTE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) and suspended in 100 μl ofbuffer A (50 mM Tris-HCl, pH 8.0, 2.4 mM phenylmethylsulfonyl fluoride,1 mM dithiothreitol, 0.5 mg/liter leupeptin, 1 mM EDTA, 250 mM KCl).Bacteria were lysed by incubating with lysozyme (0.2 mg/ml) at 0° C. for2 h. The lysate was centrifuged at 15,000 rpm (Sorvall, SA-600 rotor)(DuPont, Newtown, Conn.) for 15 min, and the supernatant solution wasincubated at 72° C. for 20 min. Insoluble material was removed bycentrifugation.

[0095] Polymerases were purified as described previously with somemodifications (Lawyer et al., PCR Methods Application 2:275-287 (1993).Briefly, a single colony of E. coli DH5α carrying wild type or mutantTaq DNA polymerase I was inoculated into 10 ml of 2×YT. Two ml of theinoculum was immediately added to each of 5 bottles containing 1 literof 2×YT with 30 mg/liter chloramphenicol. After overnight incubation at37° C. with vigorous shaking, 1 liter of 2×YT containing 30 mg/literchloramphenicol and 0.5 mM IPTG was added, and incubation was continuedfor 4 h. Cells were harvested, washed once with TE buffer and suspendedin 100 ml buffer A. Bacteria were lysed by incubating with lysozyme (0.2mg/ml) at 0° C. for 2 h and then sonicating on ice for 45 sec by using amicro-tip probe (Sonifier, Branson Sonic Power, Danbury, Conn.).

[0096] The lysate was centrifuged at 15,000 rpm (Sorvall, SA-600 rotor)for 15 min, and the supernatant solution was incubated at 72° C. for 20min. Insoluble material was removed by centrifugation. Ammonium sulfate(0.2 M) and Polymin P (0.6%) were added and the suspension was held onice for 1 h. After removal of the precipitate by centrifugation andfiltration through a Costar 8310 filter, the filtrate was applied to a3×8-cm phenyl-SEPHAROSE HP (Pharmacia Biotech) column equilibrated withbuffer A containing 0.2 M ammonium sulfate and 0.01% Triton-X-100. Thecolumn was washed with the same buffer (300 ml) and activity was elutedwith buffer B (TE buffer containing 0.01% Triton X-100 and 50 mM KCl).The eluate (100 ml) was dialyzed overnight against 4 liters of buffer Band loaded onto a 0.8×8-cm heparin-SEPHAROSE CL6B (Pharmacia Biotech)column equilibrated with buffer B. After washing with buffer B (50 ml),activity was eluted in a 30 ml linear gradient of 50-500 mM KCl in TEbuffer containing 0.01% Triton X-100. Active fractions were collected,dialyzed against 50 mM Tris-HCl (pH 8.0) containing 50 mM KCl and 50%glycerol, and stored at −80° C.

[0097] To confirm and quantitate the presence of polymerase activity,crude extracts or purified enzyme was incubated at 72° C. for 5 min in50 mM Tris-HCl (pH 8.0), 2 mM MgCl₂, 100 μM each dATP, dGTP, dCTP anddTTP, 0.2 μCi of (³H)dATP and 200 μg/ml activated calf thymus DNA.Incorporation of radioactivity into an acid-insoluble product wasmeasured according to Battula and Loeb (J. Biol. Chem. 249:4086-4093(1974). One unit represents incorporation of 10 nmol of dNMP in 1 h,corresponding to 0.1 unit as defined by Perkin-Elmer.

[0098] For the primer extension assay, the 14-mer primer5′-CGCGCCGAATTCCC (SEQ ID NO:10) was ³²P-labeled at the 5′ end byincubation with (γ⁻³²P)ATP and T4 polynucleotide kinase and annealed toan equimolar amount of the template 46-mer5′-GCGCGGAAGCTTGGCTGCAGAATATTGCTAGCGGGAATTCGGCGCG (SEQ ID NO:11).Heat-inactivated E. coli extracts containing 0.3-1 unit of wild type ormutant Taq DNA polymerases were incubated at 45° C. for 60 min in 50 mMTris-HCl (pH 8.0), 2 mM MgCl₂, 50 mM KCl, 20 μM each dATP, dGTP, dCTPand dTTP and 1.4 ng of the annealed template primer. A set of fouradditional reactions, each lacking a different dNTP, was carried out foreach polymerase. Purified enzyme (1 unit) was incubated for the timesindicated under the same conditions as for crude extracts. Afterelectrophoresis in a 14% polyacrylamide gel containing 8M urea, reactionproducts were analyzed by autoradiography. Extension was quantified byusing an NIH imaging program (see http//www.nih.gov/).

[0099] For the forward mutation assay, the non-coding strand of thelacZα gene contained in 200 ng of gapped M13mp2 DNA was copied by using5 units of wild type or mutant Taq DNA polymerase I in a reactionmixture containing 50 mM Tris-HCl (pH 8.0), 2 mM MgCl₂ and 50 mM KCl(Feig et al. Proc. Natl. Acad. Sci. USA 91:6609-6613 (1994)). Fordetermining low fidelity polymerase mutants, the reaction included 20 μMeach dNTP. For determining high fidelity polymerase mutants, thereaction was carried out with biased dNTP pools containing 0.5 mM of onedNTP and 20 mM of each of the other three dNTPs. For example, thereaction could contain 0.5 mM dATP and 20 mM each of dGTP, dCTP anddTTP. After incubation at 72° C. for 5 min, the DNA was transfected intohost E. coli and the plaques were scored for white and pale blue mutantplaques (Tindall et al., Genetics 118:551-560 (1988)).

[0100] These results show that the fidelity of active Taq DNA polymerasemutants can be determined using a primer extension assay and a forwardmutation assay.

EXAMPLE IV Identification of Low Fidelity Taq DNA Polymerase I Mutants

[0101] This example shows the identification of low fidelity Taq DNApolymerase I mutants.

[0102] The active Taq DNA polymerase I mutants identified in Example IIwere assayed by the methods described in Example III to identify lowfidelity mutants. Screening for activity was carried out on 67 of 75sequenced mutants, including all 38 with single amino acid substitutionsdescribed in FIG. 2. Plasmids encoding the mutant polymerases werecloned, purified and grown in E. coli, and host cells were analyzed forexpression of Taq DNA polymerase I by measuring the activity of crudeextracts. E. coli DNA polymerases and nucleases were inactivated byheating at 72° C. for 20 min. The ability of heat-treated extracts toelongate primers in the absence of a complete complement of four dNTPswas then determined using a set of five reactions. One reactioncontained all four complementary nucleoside triphosphates while each ofthe others lacked a different dNTP (“minus conditions”). Elongation inthe minus reactions is limited by the rate of misincorporation attemplate positions complementary to the missing dNTP.

[0103] A primer extension assay was performed on wild type Taq DNApolymerase I and several mutants, revealing that several mutants hadelongation patterns that differed from wild type Taq DNA polymerase. Inthe presence of all four dNTPs, every extract examined extended morethan 90% of the hybridized primer to a product of length similar to thatof the template. In the minus reactions, wild type Taq DNA polymerase Iextended 48-60% of the primer up to, but not opposite, the firsttemplate position complementary to the missing dNTP. The remainingprimer was terminated opposite the missing dNTP, presumably byincorporation of a single non-complementary nucleotide, or wasterminated further downstream, presumably by extension of the mispairedprimer terminus. A variety of elongation patterns was observed for the67 mutants. Thirteen mutants extended more of the primer and/orsynthesized a greater proportion of longer products than the wild typeenzyme in three or four of the minus reactions. For example, mutant 2formed full-length products in reactions lacking dGTP or dTTP. Thisincreased extension presumably reflects increased incorporation and/orextension of non-complementary nucleotides. Other mutants extended lessof the primer or synthesized shorter products than the wild type enzyme,for example, mutant 5. In several cases, different amino acidsubstitutions at the same position either increased or decreasedextension in comparable minus reactions.

[0104] A compilation of amino acid replacements in the 13 mutants thatdisplayed increased extension in at least three of the minus reactionsis shown in Table I. TABLE I Low Fidelity Mutants of Taq DNA PolymeraseI Identified in the Primer Extension Screen 659 663 667 671 WT: R R A AK T I N F G V L Y 29: E 36: P I 40: P 45: P 53: N 130: P T 156: S G S I175: W K 206: R 240: G N 247: G I 248: V 306: P I

[0105] With the exception of Gly668, one or more substitutions thatputatively reduce the accuracy of DNA synthesis were observed for eachof the 9 non-conserved amino acids. Eleven mutants harboredsubstitutions at either Ala661 or Thr664, including several singlemutants. This initial screen with crude extracts suggested that a largenumber of changes are permitted in the O-helix that do not reduce theability of Taq DNA polymerase I to complement the growth defect ofrecA718 polA12. Many of the substitutions in the O-helix that do notreduce the ability of Taq DNA polymerase I to carry out functionalcomplementation reduce the fidelity of DNA synthesis in vitro.

[0106] To demonstrate that the reduction in fidelity exhibited by crudeextracts is due to mutant Taq DNA polymerase I, wild type enzyme waspurified as well as the three single mutants Ala661Glu, Ala661Pro andThr664Arg. The mutant Ile665Thr, a mutant predicted to have noalteration in fidelity based on complementation assays, was alsopurified as a control. The mutated enzymes retained at least 29% of wildtype activity in vitro, which is in accord with their ability tocomplement the growth defect caused in E. coli by temperature-sensitivehost DNA polymerase I and ensures that analysis of fidelity will not becomplicated by major impairments of catalytic efficiency.

[0107] Primer extension assays were carried out with the homogenousmutant polymerases. Wild type Taq DNA polymerase I extended most of theprimer to one nucleotide before the template position opposite themissing complementary dNTP in a 5 min reaction. Only about 30% of theprimers were elongated further. In reactions containing equivalentactivity, the mutant polymerases Ala661Glu, Thr664Arg and Ala661Proextended a larger proportion of the primers past the sites where thewild type polymerase ceased synthesis. The control enzyme Ile665Thryielded an elongation pattern similar to that of the wild type enzyme.Elongation reactions with the three polymerases were also carried outfor 60 min. Again, Ala661Glu and Thr664Arg synthesized a greaterproportion of longer products than obtained with the wild type andIle665Thr polymerases. Notably, Ala661Glu, Thr664Arg and Ala661Prosynthesized longer products in 5 min than the wild type did in 60 min.

[0108] To further analyze the reduced fidelity exhibited by the lowfidelity polymerase mutants, a time course of primer elongation wascarried out. Wild type Taq DNA polymerase I extended 9% of the primerspast the first deoxyguanosine template residue within the 60 minincubation period, but elongation past the second deoxyguanosine was notdetected. In the same interval, Thr664Arg extended 93% of the primerpast the first template deoxyguanosine, and elongation proceeded past asmany as five template deoxyguanosines. Importantly, a comparableproportion of primers was extended at all time points, despite thestriking difference in the length of the products. These time coursedata indicate that greater elongation reflects increased ability toutilize non-complementary substrates and primer termini, rather than aputative difference in the amount of activity present.

[0109] In a forward mutation assay, the fidelity of DNA synthesis by thepurified polymerases was quantitated by measuring the frequency ofmutations produced by copying a biologically active template in vitro(Kunkel and Loeb, J. Biol. Chem 254:5718-5725 (1979)). The targetsequence was the lacZα gene located within a single-stranded region ingapped circular double-stranded M13mp2 DNA (Feig and Loeb, Biochemistry32:4466-4473 (1993)). The gapped segment was filled by synthesis withthe wild type or mutant enzymes. The double-stranded circular productwas transfected into E. coli, and the mutation frequency was determinedby scoring white and pale blue mutant plaques. A comparison of thespecific activities and mutation frequencies of the purified enzymes ispresented in Table II. After synthesis by wild type Taq DNA polymeraseI, the mutation frequency was not greater than that of the uncopiedcontrol. Synthesis by Ala661Glu and Thr664Arg gave rise to mutationfrequencies more than 7- and 25-fold greater, respectively, than that ofthe wild type polymerase. TABLE II Mutation Frequency in the lacZαForward Mutation Assay Specific Mutation Activity Plaques ScoredFrequency Taq Pol I units/mg Total Mutant x10⁻³ WT 66,000 8,637 22 2.5A661E 45,000 6,782 116 17.1 T664R 23,000 5,148 324 62.9

[0110] A sample of independent, randomly chosen mutants produced byThr664Arg was characterized by DNA sequence analysis using a THERMOSEQUENASE cycle sequencing kit (Amersham Life Science, Cleveland, Ohio).Both base substitutions and frameshifts were found throughout thetargeted lacZα gene and its regulatory sequence. Of the 64 independentplaques, 57 had mutations in the target. Other mutations presumablyoccurred outside the target region. Some had more than one basesubstitution and a total of 66 mutations were observed (see FIG. 3).Among them, 61 were base substitutions. Transitions (38/61) were morefrequent than transversions (23/61). T→C transitions accounted for 31 of61 base substitutions, while T→A (9/61), A→T (8/61) and G→A (5/61)substitutions were less frequent. This base substitution spectrum isessentially the same as that reported for wild type Taq DNA polymerase I(Tindall and Kunkel, supra, 1988). From these data, the basesubstitution fidelity of Thr664Arg can be calculated as 8.6×10⁻⁴ or 1error per 1200 nucleotides. On the basis of the five frameshift mutantsdetected, the frameshift error can be calculated as 4.9×10⁻⁵ or 1 errorper 20,000 nucleotides.

[0111] These results show that low fidelity Taq DNA polymerase I mutantswere identified from a randomized library using a geneticcomplementation screen. The fidelity of Taq DNA polymerase I mutants wasdetermined by primer extension assays and forward mutation assays.

EXAMPLE V Identification of High Fidelity Taq DNA Polymerase I Mutants

[0112] This example shows the identification of high fidelity Taq DNApolymerase I mutants.

[0113] The active Taq DNA polymerase I mutants identified in Example IIwere assayed by the methods described in Example III to identify highfidelity mutants. A panel of 75 active polymerases was screened.Candidate high fidelity polymerase mutants are shown in Table III. TABLEIII Candidate High Fidelity Mutants of Taq DNA Polymerase I 659 663 667671 WT: R R A A K T I N F G V L Y FL: L 74: E T L 146: D 147: I 149: I D169: S L 186: L 219: P V Y 254: V 407: Y 424: Y 426: S 487: R 488: K530: S 614: Q

[0114] Thirteen of the active polymerases exhibited greater accuracy inDNA synthesis. Table IV summarizes the results of a forward mutationassay of some of these high fidelity mutants. Several polymerase mutantsdisplayed higher fidelity than the wild type Taq DNA polymerase.Polymerase mutants exhibiting particularly high fidelity are mutant 424,with Phe667Tyr, mutant 426, with Arg660Ser and mutant 488, withArg660Lys. TABLE IV Fidelity of Taq DNA Polymerase Mutants in a lacZForward Mutation Assay Mutation Total Mutant Frequency Enzyme PlaquesPlaques x10⁻³ Wild Type 5680 49 8.6 High Fidelity Mutants MS147 7249 476.5 MS169 7275 34 5.1 MS254 6898 40 5.8 MS424 4810 14 2.7 MS426 5727 234.1 MS488 3442 13 1.5 Low Fidelity Mutant MS206 3333 133 40

[0115] These results show that Taq DNA polymerase mutants wereidentified and found to exhibit higher fidelity than wild type Taq DNApolymerase.

EXAMPLE VI High Fidelity Taq DNA Polymerase Mutants Enhance theSensitivity of Mismatch PCR-based Assays for Somatic Mutations

[0116] This example shows the use of high fidelity mutants obtained bymutating the active site O-helix of Taq DNA polymerase I to enhance thesensitivity of mismatch PCR-based assays for somatic mutations.

[0117] Mismatch PCR is the basis of allele-specific identification ofinherited mutations within genes and somatic mutations that occur intumors. In these studies, one compares the extension of a correctlymatched primer with the lack of extension using a primer with a3′-terminal mismatch. The rate of extension by DNA polymerase using aprimer with a single mismatch compared to a primer with a3′-complementary base pair (matched) terminus is approximately 10⁻⁵(Perinno and Loeb, J. Biol. Chem. 262:2898-2905 (1989)). Elongation froma double mismatch is even less frequent, and thus offers an even morestringent test of the inability of mutant Taq DNA polymerases toelongate a mismatched primer terminus.

[0118] A template containing the wild type sequence of human DNApolymerase-β at nucleotide positions 886-889 (CCCCTGGG) was utilized.PCR reactions were carried out with two complementary primers that flankthe sequence (matched) or with one matched template and a secondmismatched template containing a terminally mismatched primer with AA atthe 3′ terminal position. The AA would be across from the CC(underlined) in the template strand. In these studies, the ratio oftemplates containing the complementary and non-complementary sequenceswere varied. The PCR amplified product was separated by polyacrylamidegel electrophoresis and quantitated by phosphoimage analysis. Wild typeTaq DNA polymerase detected one molecule of template containing a TTsubstitution in place of the two template CC when present in apopulation of 10⁵ molecules containing the non-mutant templates with theCC substitution. In contrast, both of the high fidelity Taq DNApolymerase mutants, with substitutions Phe667Tyr and Arg659Ser, detectedone molecule of the TT template amongst 10⁸ molecules of the CC templatewhen the primer contained two terminal 3′-AA nucleotide residues.

[0119] These results show that high fidelity Taq DNA polymerase mutantshave two to three orders of magnitude enhanced sensitivity for detectingmutant DNA using a mismatch PCR-based assay.

EXAMPLE VII High Fidelity Taq DNA Polymerase Mutants Enhance Sensitivityof Detection of Repetitive DNA Sequences

[0120] This example demonstrates the use of high fidelity polymerasemutants to enhance the sensitivity and accuracy of amplifying repetitiveDNA sequences.

[0121] Detection of the length of unstable microsatellite DNA in certainhuman tumors has depended on PCR amplification of specific sequences anddetermination of changes in electrophoretic mobility in gels. Due to theslippage of DNA polymerase while copying repetitive DNA, theinterpretation of the results of this method have remainedunsatisfactory.

[0122] High fidelity Taq DNA polymerases are identified using themethods described in Examples I and III. DNA templates containing runsof CA repeats with the number of repeats varying from 5 to 50 are usedto test high fidelity Taq DNA polymerase mutants. After 20 to 70 roundsof PCR amplification, the product of the reaction is displayed onpolyacrylamide gels. High fidelity polymerase mutants which display lessslippage errors copying the repetitive sequences are identified. Thesehigh fidelity polymerase mutants are used to amplify repetitive DNAsequences in samples, for example tissue or tumor samples.

[0123] These results show that high fidelity mutants having enhancedsensitivity and accuracy in amplifying repetitive DNA sequences can beidentified and used to amplify repetitive DNA in tissue or tumorsamples.

[0124] Throughout this application various publications have beenreferenced. The disclosures of these publications in their entiretiesare hereby incorporated by reference in this application in order tomore fully describe the state of the art to which this inventionpertains.

[0125] Although the invention has been described with reference to thedisclosed embodiments, those skilled in the art will readily appreciatethat the specific experiments detailed are only illustrative of theinvention. It should be understood that various modifications can bemade without departing from the spirit of the invention.

1 11 2626 base pairs nucleic acid both linear CDS 121..2616 1 AAGCTCAGATCTACCTGCCT GAGGGCGTCC GGTTCCAGCT GGCCCTTCCC GAGGGGGAGA 60 GGGAGGCGTTTCTAAAAGCC CTTCAGGACG CTACCCGGGG GCGGGTGGTG GAAGGGTAAC 120 ATG AGG GGGATG CTG CCC CTC TTT GAG CCC AAG GGC CGG GTC CTC CTG 168 Met Arg Gly MetLeu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15 GTG GAC GGCCAC CAC CTG GCC TAC CGC ACC TTC CAC GCC CTG AAG GGC 216 Val Asp Gly HisHis Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly 20 25 30 CTC ACC ACC AGCCGG GGG GAG CCG GTG CAG GCG GTC TAC GGC TTC GCC 264 Leu Thr Thr Ser ArgGly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala 35 40 45 AAG AGC CTC CTC AAGGCC CTC AAG GAG GAC GGG GAC GCG GTG ATC GTG 312 Lys Ser Leu Leu Lys AlaLeu Lys Glu Asp Gly Asp Ala Val Ile Val 50 55 60 GTC TTT GAC GCC AAG GCCCCC TCC TTC CGC CAC GAG GCC TAC GGG GGG 360 Val Phe Asp Ala Lys Ala ProSer Phe Arg His Glu Ala Tyr Gly Gly 65 70 75 80 TAC AAG GCG GGC CGG GCCCCC ACG CCG GAG GAC TTT CCC CGG CAA CTC 408 Tyr Lys Ala Gly Arg Ala ProThr Pro Glu Asp Phe Pro Arg Gln Leu 85 90 95 GCC CTC ATC AAG GAG CTG GTGGAC CTC CTG GGG CTG GCG CGC CTC GAG 456 Ala Leu Ile Lys Glu Leu Val AspLeu Leu Gly Leu Ala Arg Leu Glu 100 105 110 GTC CCG GGC TAC GAG GCG GACGAC GTC CTG GCC AGC CTG GCC AAG AAG 504 Val Pro Gly Tyr Glu Ala Asp AspVal Leu Ala Ser Leu Ala Lys Lys 115 120 125 GCG GAA AAG GAG GGC TAC GAGGTC CGC ATC CTC ACC GCC GAC AAA GAC 552 Ala Glu Lys Glu Gly Tyr Glu ValArg Ile Leu Thr Ala Asp Lys Asp 130 135 140 CTT TAC CAG CTC CTT TCC GACCGC ATC CAC GTC CTC CAC CCC GAG GGG 600 Leu Tyr Gln Leu Leu Ser Asp ArgIle His Val Leu His Pro Glu Gly 145 150 155 160 TAC CTC ATC ACC CCG GCCTGG CTT TGG GAA AAG TAC GGC CTG AGG CCC 648 Tyr Leu Ile Thr Pro Ala TrpLeu Trp Glu Lys Tyr Gly Leu Arg Pro 165 170 175 GAC CAG TGG GCC GAC TACCGG GCC CTG ACC GGG GAC GAG TCC GAC AAC 696 Asp Gln Trp Ala Asp Tyr ArgAla Leu Thr Gly Asp Glu Ser Asp Asn 180 185 190 CTT CCC GGG GTC AAG GGCATC GGG GAG AAG ACG GCG AGG AAG CTT CTG 744 Leu Pro Gly Val Lys Gly IleGly Glu Lys Thr Ala Arg Lys Leu Leu 195 200 205 GAG GAG TGG GGG AGC CTGGAA GCC CTC CTC AAG AAC CTG GAC CGG CTG 792 Glu Glu Trp Gly Ser Leu GluAla Leu Leu Lys Asn Leu Asp Arg Leu 210 215 220 AAG CCC GCC ATC CGG GAGAAG ATC CTG GCC CAC ATG GAC GAT CTG AAG 840 Lys Pro Ala Ile Arg Glu LysIle Leu Ala His Met Asp Asp Leu Lys 225 230 235 240 CTC TCC TGG GAC CTGGCC AAG GTG CGC ACC GAC CTG CCC CTG GAG GTG 888 Leu Ser Trp Asp Leu AlaLys Val Arg Thr Asp Leu Pro Leu Glu Val 245 250 255 GAC TTC GCC AAA AGGCGG GAG CCC GAC CGG GAG AGG CTT AGG GCC TTT 936 Asp Phe Ala Lys Arg ArgGlu Pro Asp Arg Glu Arg Leu Arg Ala Phe 260 265 270 CTG GAG AGG CTT GAGTTT GGC AGC CTC CTC CAC GAG TTC GGC CTT CTG 984 Leu Glu Arg Leu Glu PheGly Ser Leu Leu His Glu Phe Gly Leu Leu 275 280 285 GAA AGC CCC AAG GCCCTG GAG GAG GCC CCC TGG CCC CCG CCG GAA GGG 1032 Glu Ser Pro Lys Ala LeuGlu Glu Ala Pro Trp Pro Pro Pro Glu Gly 290 295 300 GCC TTC GTG GGC TTTGTG CTT TCC CGC AAG GAG CCC ATG TGG GCC GAT 1080 Ala Phe Val Gly Phe ValLeu Ser Arg Lys Glu Pro Met Trp Ala Asp 305 310 315 320 CTT CTG GCC CTGGCC GCC GCC AGG GGG GGC CGG GTC CAC CGG GCC CCC 1128 Leu Leu Ala Leu AlaAla Ala Arg Gly Gly Arg Val His Arg Ala Pro 325 330 335 GAG CCT TAT AAAGCC CTC AGG GAC CTG AAG GAG GCG CGG GGG CTT CTC 1176 Glu Pro Tyr Lys AlaLeu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu 340 345 350 GCC AAA GAC CTGAGC GTT CTG GCC CTG AGG GAA GGC CTT GGC CTC CCG 1224 Ala Lys Asp Leu SerVal Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro 355 360 365 CCC GGC GAC GACCCC ATG CTC CTC GCC TAC CTC CTG GAC CCT TCC AAC 1272 Pro Gly Asp Asp ProMet Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn 370 375 380 ACC ACC CCC GAGGGG GTG GCC CGG CGC TAC GGC GGG GAG TGG ACG GAG 1320 Thr Thr Pro Glu GlyVal Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu 385 390 395 400 GAG GCG GGGGAG CGG GCC GCC CTT TCC GAG AGG CTC TTC GCC AAC CTG 1368 Glu Ala Gly GluArg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu 405 410 415 TGG GGG AGGCTT GAG GGG GAG GAG AGG CTC CTT TGG CTT TAC CGG GAG 1416 Trp Gly Arg LeuGlu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu 420 425 430 GTG GAG AGGCCC CTT TCC GCT GTC CTG GCC CAC ATG GAG GCC ACG GGG 1464 Val Glu Arg ProLeu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly 435 440 445 GTG CGC CTGGAC GTG GCC TAT CTC AGG GCC TTG TCC CTG GAG GTG GCC 1512 Val Arg Leu AspVal Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala 450 455 460 GAG GAG ATCGCC CGC CTC GAG GCC GAG GTC TTC CGC CTG GCC GGC CAC 1560 Glu Glu Ile AlaArg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His 465 470 475 480 CCC TTCAAC CTC AAC TCC CGG GAC CAG CTG GAA AGG GTC CTC TTT GAC 1608 Pro Phe AsnLeu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp 485 490 495 GAG CTAGGG CTT CCC GCC ATC GGC AAG ACG GAG AAG ACC GGC AAG CGC 1656 Glu Leu GlyLeu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg 500 505 510 TCC ACCAGC GCC GCC GTC CTG GAG GCC CTC CGC GAG GCC CAC CCC ATC 1704 Ser Thr SerAla Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile 515 520 525 GTG GAGAAG ATC CTG CAG TAC CGG GAG CTC ACC AAG CTG AAG AGC ACC 1752 Val Glu LysIle Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr 530 535 540 TAC ATTGAC CCC TTG CCG GAC CTC ATC CAC CCC AGG ACG GGC CGC CTC 1800 Tyr Ile AspPro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu 545 550 555 560 CACACC CGC TTC AAC CAG ACG GCC ACG GCC ACG GGC AGG CTA AGT AGC 1848 His ThrArg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser 565 570 575 TCCGAT CCC AAC CTC CAG AAC ATC CCC GTC CGC ACC CCG CTT GGG CAG 1896 Ser AspPro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln 580 585 590 AGGATC CGC CGG GCC TTC ATC GCC GAG GAG GGG TGG CTA TTG GTG GCC 1944 Arg IleArg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala 595 600 605 CTGGAC TAT AGC CAG ATA GAG CTC AGG GTG CTG GCC CAC CTC TCC GGC 1992 Leu AspTyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly 610 615 620 GACGAG AAC CTG ATC CGG GTC TTC CAG GAG GGG CGG GAC ATC CAC ACG 2040 Asp GluAsn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr 625 630 635 640GAG ACC GCC AGC TGG ATG TTC GGC GTC CCC CGG GAG GCC GTG GAC CCC 2088 GluThr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro 645 650 655CTG ATG CGC CGG GCG GCC AAG ACC ATC AAC TTC GGG GTC CTC TAC GGC 2136 LeuMet Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly 660 665 670ATG TCG GCC CAC CGC CTC TCC CAG GAG CTA GCC ATC CCT TAC GAG GAG 2184 MetSer Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu 675 680 685GCC CAG GCC TTC ATT GAG CGC TAC TTT CAG AGC TTC CCC AAG GTG CGG 2232 AlaGln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg 690 695 700GCC TGG ATT GAG AAG ACC CTG GAG GAG GGC AGG AGG CGG GGG TAC GTG 2280 AlaTrp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val 705 710 715720 GAG ACC CTC TTC GGC CGC CGC CGC TAC GTG CCA GAC CTA GAG GCC CGG 2328Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg 725 730735 GTG AAG AGC GTG CGG GAG GCG GCC GAG CGC ATG GCC TTC AAC ATG CCC 2376Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro 740 745750 GTC CAG GGC ACC GCC GCC GAC CTC ATG AAG CTG GCT ATG GTG AAG CTC 2424Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu 755 760765 TTC CCC AGG CTG GAG GAA ATG GGG GCC AGG ATG CTC CTT CAG GTC CAC 2472Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His 770 775780 GAC GAG CTG GTC CTC GAG GCC CCA AAA GAG AGG GCG GAG GCC GTG GCC 2520Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala 785 790795 800 CGG CTG GCC AAG GAG GTC ATG GAG GGG GTG TAT CCC CTG GCC GTG CCC2568 Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro 805810 815 CTG GAG GTG GAG GTG GGG ATA GGG GAG GAC TGG CTC TCC GCC AAG GAG2616 Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu 820825 830 TGATACCACC 2626 832 amino acids amino acid linear protein 2 MetArg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu 1 5 10 15Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly 20 25 30Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala 35 40 45Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val 50 55 60Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly 65 70 7580 Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu 85 9095 Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu 100105 110 Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys115 120 125 Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp LysAsp 130 135 140 Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His ProGlu Gly 145 150 155 160 Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys TyrGly Leu Arg Pro 165 170 175 Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr GlyAsp Glu Ser Asp Asn 180 185 190 Leu Pro Gly Val Lys Gly Ile Gly Glu LysThr Ala Arg Lys Leu Leu 195 200 205 Glu Glu Trp Gly Ser Leu Glu Ala LeuLeu Lys Asn Leu Asp Arg Leu 210 215 220 Lys Pro Ala Ile Arg Glu Lys IleLeu Ala His Met Asp Asp Leu Lys 225 230 235 240 Leu Ser Trp Asp Leu AlaLys Val Arg Thr Asp Leu Pro Leu Glu Val 245 250 255 Asp Phe Ala Lys ArgArg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe 260 265 270 Leu Glu Arg LeuGlu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu 275 280 285 Glu Ser ProLys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly 290 295 300 Ala PheVal Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp 305 310 315 320Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro 325 330335 Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu 340345 350 Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro355 360 365 Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro SerAsn 370 375 380 Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu TrpThr Glu 385 390 395 400 Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg LeuPhe Ala Asn Leu 405 410 415 Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu LeuTrp Leu Tyr Arg Glu 420 425 430 Val Glu Arg Pro Leu Ser Ala Val Leu AlaHis Met Glu Ala Thr Gly 435 440 445 Val Arg Leu Asp Val Ala Tyr Leu ArgAla Leu Ser Leu Glu Val Ala 450 455 460 Glu Glu Ile Ala Arg Leu Glu AlaGlu Val Phe Arg Leu Ala Gly His 465 470 475 480 Pro Phe Asn Leu Asn SerArg Asp Gln Leu Glu Arg Val Leu Phe Asp 485 490 495 Glu Leu Gly Leu ProAla Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg 500 505 510 Ser Thr Ser AlaAla Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile 515 520 525 Val Glu LysIle Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr 530 535 540 Tyr IleAsp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu 545 550 555 560His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser 565 570575 Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln 580585 590 Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala595 600 605 Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu SerGly 610 615 620 Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp IleHis Thr 625 630 635 640 Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg GluAla Val Asp Pro 645 650 655 Leu Met Arg Arg Ala Ala Lys Thr Ile Asn PheGly Val Leu Tyr Gly 660 665 670 Met Ser Ala His Arg Leu Ser Gln Glu LeuAla Ile Pro Tyr Glu Glu 675 680 685 Ala Gln Ala Phe Ile Glu Arg Tyr PheGln Ser Phe Pro Lys Val Arg 690 695 700 Ala Trp Ile Glu Lys Thr Leu GluGlu Gly Arg Arg Arg Gly Tyr Val 705 710 715 720 Glu Thr Leu Phe Gly ArgArg Arg Tyr Val Pro Asp Leu Glu Ala Arg 725 730 735 Val Lys Ser Val ArgGlu Ala Ala Glu Arg Met Ala Phe Asn Met Pro 740 745 750 Val Gln Gly ThrAla Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu 755 760 765 Phe Pro ArgLeu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His 770 775 780 Asp GluLeu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala 785 790 795 800Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro 805 810815 Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu 820825 830 39 base pairs nucleic acid single linear 3 GGGTCCACGG CCTCCCGCGGGACGCCGAAC ATCCAGCTG 39 16 base pairs nucleic acid single linear 4GGACTGCATA TGACTG 16 22 base pairs nucleic acid single linear 5CTAGCAGTCA TATGCAGTCC GC 22 80 base pairs nucleic acid single linear 6CGGGAGGCCG TGGACCCCCT GATGCGCCGG GCGGCCAAGA CCATCAACTT CGGGGTCCTC 60TACGGCATGT CGGCCCACCG 80 37 base pairs nucleic acid single linear 7TGGCTAGCTC CTGGGAGAGG CGGTGGGCCG ACATGCC 37 32 base pairs nucleic acidsingle linear 8 TTCGGCGTCC CGCGGGAGGC CGTGGACCCC CT 32 24 base pairsnucleic acid single linear 9 GTAAGGGATG GCTAGCTCCT GGGA 24 14 base pairsnucleic acid single linear 10 CGCGCCGAAT TCCC 14 46 base pairs nucleicacid single linear 11 GCGCGGAAGC TTGGCTGCAG AATATTGCTA GCGGGAATTC GGCGCG46

We claim:
 1. A method for identifying a thermostable polymerase havingaltered fidelity, comprising generating a random population ofpolymerase mutants by mutating at least one amino acid residue of athermostable polymerase and screening said population for one or moreactive polymerase mutants by genetic selection.
 2. The method of claim1, wherein two or more amino acid residues of said thermostablepolymerase are mutated.
 3. The method of claim 1, further comprisingdetermining a fidelity of said active polymerase mutant.
 4. The methodof claim 1, wherein said mutated amino acid residue is adjacent to animmutable or nearly immutable residue.
 5. The method of claim 4, whereinsaid mutated amino acid residue is immediately adjacent to an immutableor nearly immutable residue.
 6. The method of claim 1, wherein saidmutated amino acid residue is in an O-helix of a thermostablepolymerase.
 7. The method of claim 4, wherein said mutated amino acidresidue is adjacent to an amino acid residue corresponding to Arg659,Lys663, Phe667 or Tyr671 in Taq DNA polymerase.
 8. The method of claim7, wherein said thermostable polymerase is Taq DNA polymerase.
 9. Amethod for identifying a thermostable polymerase having alteredfidelity, comprising generating a random population of polymerasemutants by mutating at least one amino acid residue in an active siteO-helix of a thermostable polymerase and screening said population forone or more active polymerase mutants.
 10. The method of claim 9,wherein two or more amino acid residues of said thermostable polymeraseis mutated.
 11. The method of claim 9, further comprising determining afidelity of said active polymerase mutant.
 12. The method of claim 9,wherein said mutated amino acid residue is adjacent to an immutable ornearly immutable residue.
 13. The method of claim 12, wherein saidmutated amino acid residue is immediately adjacent to an immutable ornearly immutable residue.
 14. The method of claim 12, wherein said oneor more amino acid residues is adjacent to an amino acid residuecorresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNA polymerase.15. The method of claim 14, wherein said thermostable polymerase is TaqDNA polymerase.
 16. An isolated thermostable polymerase mutant havingaltered fidelity, wherein said mutant comprises one or more mutatedamino acid residues in the active site O-helix of a thermostablepolymerase.
 17. The polymerase mutant of claim 16, wherein saidpolymerase is Taq DNA polymerase.
 18. The polymerase mutant of claim 16,wherein said mutated amino acid residue is adjacent to an immutable ornearly immutable residue.
 19. The polymerase mutant of claim 18, whereinsaid mutated amino acid residue is immediately adjacent to an immutableor nearly immutable residue.
 20. The polymerase mutant of claim 18,wherein said mutated amino acid residue is adjacent to an amino acidresidue corresponding to Arg659, Lys663, Phe667 or Tyr671 in Taq DNApolymerase.
 21. The polymerase mutant of claim 20, wherein saidpolymerase is Taq DNA polymerase.
 22. The polymerase mutant of claim 17,wherein said polymerase mutant is a high fidelity mutant.
 23. Thepolymerase mutant of claim 22, wherein said polymerase mutant comprisesone or more amino acid substitutions selected from the group consistingof Phe667Leu; Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr;Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile andAsn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu;and Thr664Pro, Ile665Val and Asn666Tyr.
 24. The polymerase mutant ofclaim 17, wherein said polymerase mutant is a low fidelity mutant. 25.The polymerase mutant of claim 24, wherein said polymerase mutantcomprises substitution of one or more amino acids selected from thegroup consisting of Ala661, Thr664, Asn666 and Leu670.
 26. Thepolymerase mutant of claim 25, wherein said polymerase mutant comprisesone or more amino acid substitutions selected from the group consistingof Ala661Glu; Ala661Pro; Thr664Pro; Thr664Asn; Thr664Arg; Asn666Val;Thr664Pro and Val669Ile; Arg660Pro and Leu670Thr; Arg660Trp andThr664Lys; Ala662Gly and Thr664Asn; Ala661Gly and Asn666Ile; Ala661Proand Asn666Ile; and Ala661Ser, Ala662Gly, Thr664Ser and Asn666Ile.
 27. Anisolated nucleic acid molecule encoding a polymerase mutant having highfidelity, comprising a nucleotide sequence encoding substantially anamino acid sequence of Taq DNA polymerase I comprising one or more aminoacid substitutions selected from the group consisting of Phe667Leu;Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr; Arg660Ser;Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile and Asn666Asp;Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu; andThr664Pro, Ile665Val and Asn666Tyr.
 28. An isolated nucleic acidmolecule encoding a polymerase mutant having low fidelity, comprising anucleotide sequence encoding substantially an amino acid sequence of TaqDNA polymerase I comprising substitution of one or more amino acidsselected from the group consisting of Ala661, Thr664, Asn666 and Leu670.29. The nucleic acid molecule of claim 28, wherein said polymerasemutant comprises one or more amino acid substitutions selected from thegroup consisting of Ala661Glu; Ala661Pro; Thr664Pro; Thr664Asn;Thr664Arg; Asn666Val; Thr664Pro and Val669Ile; Arg660Pro and Leu670Thr;Arg660Trp and Thr664Lys; Ala662Gly and Thr664Asn; Ala661Gly andAsn666Ile; Ala661Pro and Asn666Ile; and Ala661Ser, Ala662Gly, Thr664Serand Asn666Ile.
 30. A method for identifying one or more mutations in agene, comprising amplifying said gene using a high fidelity polymerasemutant under conditions which allow polymerase chain reactionamplification.
 31. A method for identifying one or more mutations in agene, comprising amplifying said gene using the high fidelity polymerasemutant of claim 22 under conditions which allow polymerase chainreaction amplification.
 32. The method of claim 30, wherein said gene isamplified by exposing the strands of said gene to repeated cycles ofdenaturing, annealing and elongation to produce an amplified product.33. The method of claim 32, further comprising determining the presenceor absence of one or more mutations in the sequence of said gene. 34.The method of claim 30, wherein said polymerase mutant comprises one ormore amino acid substitutions selected from the group consisting ofPhe667Leu; Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr;Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile andAsn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu;and Thr664Pro, Ile665Val and Asn666Tyr.
 35. A method for accuratelycopying repetitive nucleotide sequences, comprising amplifying saidrepetitive nucleotide sequence using a high fidelity polymerase mutant.36. The method of claim 35, wherein said repetitive nucleotide sequenceis in a gene.
 37. The method of claim 35, wherein said repetitivenucleotide sequence is in a microsatellite between genes.
 38. A methodfor accurately copying repetitive nucleotide sequences, comprisingamplifying said repetitive nucleotide sequence using said high fidelitypolymerase mutant of claim
 22. 39. A method for determining an inheritedmutation, comprising amplifying a gene using a high fidelity polymerasemutant.
 40. A method for diagnosing a genetic disease, comprisingcorrelating the inherited mutation determined in claim 39 with saidgenetic disease.
 41. A method for diagnosing a genetic disease,comprising amplifying a gene using a high fidelity polymerase mutant.42. A method for diagnosing a genetic disease, comprising amplifying agene using said high fidelity polymerase mutant of claim
 22. 43. Themethod of claim 41, wherein said genetic disease comprises mutations inmicrosatellite or repetitive DNA.
 44. The method of claim 43, whereinsaid genetic disease is cancer.
 45. A method for determining theprognosis of a genetic disease, comprising amplifying said gene in claim41.
 46. The method of claim 41, wherein said polymerase mutant comprisesone or more amino acid substitutions selected from the group consistingof Phe667Leu; Asn666Asp; Asn666Ile; Ile665Leu; Leu670Val; Arg660Tyr;Arg660Ser; Gly668Arg; Arg660Lys; Gly668Ser; Gly668Gln; Thr664Ile andAsn666Asp; Ala661Ser and Val669Leu; Ala661Glu, Ile665Thr, and Phe667Leu;and Thr664Pro, Ile665Val and Asn666Tyr.
 47. A method for randomlymutagenizing a gene, comprising amplifying said gene using a lowfidelity polymerase mutant.
 48. A method for randomly mutagenizing agene, comprising amplifying said gene using said low fidelity polymerasemutant of claim
 24. 49. The method of claim 48, wherein said polymerasemutant comprises substitution of one or more amino acid residuesselected from the group consisting of Ala661, Thr664, Asn666 and Leu670.50. The method of claim 49, wherein said polymerase mutant comprises oneor more amino acid substitutions selected from the group consisting ofAla661Glu; Ala661Pro; Thr664Pro; Thr664Asn; Thr664Arg; Asn666Val;Thr664Pro and Val669Ile; Arg660Pro and Leu670Thr; Arg660Trp andThr664Lys; Ala662Gly and Thr664Asn; Ala661Gly and Asn666Ile; Ala661Proand Asn666Ile; and Ala661Ser, Ala662Gly, Thr664Ser and Asn666Ile.